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1 
1 Introduction 
The hepatitis C virus (HCV) was identified in 1989, although the existence of the non-A, non-B 
hepatitis virus, as a causative agent of post-transfusion hepatitis, was postulated much earlier 1,2. 
Currently, about 3 % of the world population (~ 160 million people) is infected with HCV. Only 
in 20 to 30 % of cases of acute HCV infections the virus is cleared spontaneously 3. In other 70 
to 80 % of cases the initial infection leads to a persistent viremia accompanied by hepatic 
inflammation and fibrosis of variable degrees; these patients have an increased risk to develop 
liver cirrhosis and hepatocellular carcinoma (HCC) 4. 
The standard therapy of chronic HCV infection at the moment consists of pegylated alpha 
interferon (IFN-α) in combination with ribavirin and is effective only in 40-60 % of infected 
individuals depending on the HCV genotype. Recently, two protease inhibitors, boceprevir and 
telaprevir, that target the viral NS3/4A protease have been introduced into medical practice to 
treat patients with chronic hepatitis C. Application of these inhibitors in combination with the 
standard IFN-α and ribavirin therapy increased the sustained virological response (SVR) against 
HCV genotype 1 strains up to 75 % 5,6. 
 
1.1 HCV genome organization 
The hepatitis C virus is a member of the Flaviviridae family, which is divided into three genera. 
The flavivirus group includes yellow fever virus, dengue fever virus, tick-borne encephalitis 
virus and Japanese encephalitis virus, whereas classical swine fever virus, bovine viral diarrhea 
virus, and Border disease virus belong to the pestiviruses. HCV is a member of the hepacivirus 
genus (also includes the GB virus B and GB virus C) and is divided into seven major genotypes 
and numerous subtypes 7,8. 
HCV is an icosahedral virus with a diameter of 50 to 70 nm. The viral particles have an envelope 
formed by a host-derived lipid bilayer that anchors the viral envelope glycoproteins E1 and E2 9. 
The viral envelope encloses the spherical nucleocapsid, which consists of multimerized core 
protein (C), and contains a single positively oriented RNA genome molecule of 9.6 kilobases 
(kb). The single open reading frame (ORF) encodes a polyprotein of 3000 amino acids (aa) and 
is flanked by 5‘ and 3‘ untranslated regions (UTR), which are essential for RNA replication and 
polyprotein translation 10. The most conserved region of the HCV genome is the 5‘UTR with a 
size of 341 nucleotides (nt). It is located upstream of the codon for initiation of translation, and 
contains four highly conserved structured domains (I-IV) with a number of stem-loops and one 
pseudoknot 11,12. The IRES (internal ribosome entry site) is formed by the domains II, III and IV 
of the 5‘-UTR in combination with the first 12 to 30 nt of the core-coding region 13. The 
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2 
canonical translation initiation factors are not needed for the translation of the HCV polyprotein 
due to a capability of the IRES to form a stable pre-initiation complex with the ribosomal 40S 
subunit. The 3‘UTR consist of approximately 225 nt and is separated into three regions, starting 
with a so-called variable region of 30 - 40 nt, followed by a long poly-(UC) tract, and a highly 
conserved 3‘-terminal region of 98 nt (3‘X region) that contains three stem-loop structures SL1, 
SL2 and SL3 14-16. The 3‘X region and 52 nt located upstream of the poly-(U/C) tract are 
essential for viral RNA replication, and the remaining part of the 3‘UTR functions as enhancer 
sequence for viral replication 17-20. 
The viral polyprotein is processed by virus and host derived proteases and cleaved into 10 
polypeptides: core (C), envelope 1 (E1), envelope 2 (E2), p7 (nonstructural protein 1, NS1), 
nonstructural protein 2 (NS2), nonstructural protein 3 (NS3), nonstructural proteins 4A and 4B 
(NS4A and NS4B), and nonstructural proteins 5A and 5B (NS5A and NS5B) (Fig.1.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  1.1 The HCV genome and polyprotein.  
 The RNA genome comprises a 9.6-kb RNA of plus strand polarity. Post-translational 
cleavages by SPP (signal peptide peptidase), SP (signal peptidase), NS2-3 pro (NS2–
NS3 cysteine protease), and NS3 pro/4A (NS3 serine protease and NS4A complex) 
lead to the production of functional HCV proteins. Functions of each protein in the 
viral lifecycle are indicated below the open reading frame 21. 
Suzuki Assembly of HCV
FIGURE 1 |The HCV genome and polyprotein.The RNA genome
compris s a 9.6-kb RNA of plus trand polarity. Post-tran la io al cle vages
by SPP (signal peptide peptidase), SP (signal peptidase), NS2-3 pro
(NS2–NS3 cysteine protease), and NS3 pro/4A (NS3 serine protease and
NS4A complex) lead to the production of functional HCV proteins.
Functions of each protein in the viral lifecycle are indicated below the open
reading frame.
NS4A serves as a cofactor for NS3 and is involved in targeting NS3
to the ER membrane (Wolk et al., 2000). NS4B plays a role in the
remodeling of host-cell membranes, probably to generate a site
for replicase assembly. NS5A is also thought to play an important
but undefined role in viral RNA replication. NS5B functions as an
RNA-dependent RNA polymerase. The role of HCV NS proteins
in assembly of the infectious virion is described below.
CORE PROTEIN AND NUCLEOCAPSID FORMATION
TheCore is 191 aa in length and consists of three distinct predicted
domains: an N-terminal domain that is two-thirds hydrophilic, a
C-terminal domain that is one-third hydrophobic, and a short sig-
nal peptide sequence of the downstreamprotein E1. The precursor
Core is cleaved between Core and E1 by a host signal peptidase.
A C-terminal membrane-anchor of the Core is further cleaved
by a signal peptide peptidase. The mature Core is estimated to
be 177–179 aa (Ogino et al., 2004; Okamoto et al., 2004). Mat-
uration of the Core by a signal peptide peptidase is required for
virion production (Okamoto et al., 2008; Targett-Adams et al.,
2008). Biophysical techniques have been used to demonstrate
that the mature Core is a dimeric alpha-helical protein (Boulant
et al., 2005). Its aa sequence is highly conserved among different
HCV strains, compared with other HCV proteins. Thus, Core is
used in most serologic assays since anti-core antibodies are highly
prevalent among HCV-infected individuals.
Core has been detected in a number of subcellular compart-
ments. Core protein is found on ER membranes, on the surface
of lipid droplets (LDs), on the mitochondrial outer membrane,
and to some extent, in the nucleus (Moradpour et al., 1996; Barba
et al., 1997; Moriya et al., 1998; Yasui et al., 1998; Hope et al.,
2002; Suzuki et al., 2005). Following is a proposed mechanism of
translocation of Core to membranes within the ER network such
as LDs (McLauchlan et al., 2002; Schwer et al., 2004). After being
processed by a signal peptide peptidase, a large part of the Core
remains within cytoplasmic leaflets of the ER membrane due to
preservation of the original transmembrane domain. The cyto-
plasmic leaflets then swell as lipid accumulates between the two
membrane leaflets. As a result, the Core is translocated along with
part of the ERmembrane to the surface of a nascent LD before the
droplet buds off the ER. The proteasome-dependent degradation
pathway thenparticipates in post-translationalmodification of the
Core (Suzuki et al., 2001, 2009; Moriishi et al., 2003, 2007, 2010;
Shirakura et al., 2007). Ubiquitin ligase E6AP and proteasome
activator PA28gamma are key regulators in determining the fate
of the Core, and thereby play a role in virus production (Shirakura
et al., 2007; Moriishi et al., 2010).
The ∼120 N-terminal residues of the Core protein (domain I)
contain multiple positively charged residues that are implicated
in RNA binding and homo-oligomerization. It is therefore likely
that this domain is a prerequisite for assembly of the HCV nucle-
ocapsid (Kunkel et al., 2001; Klein et al., 2004, 2005; Majeau et al.,
2004). It has been shown that a region extending from aa 72 to 91 is
responsible for auto-oligomerization of Core (Nakai et al., 2006).
Although conclusive data for direct packaging of theHCV genome
into the viral capsid is lacking, the viral RNA sequence of the Core
protein through to the NS2 region appears not to contain a cis-
acting packaging signal. A subgenomic replicon RNA carrying the
NS3–NS5B region canbe encapsidated in the viral trans-packaging
system (Ishii et al., 2008; Steinmann et al., 2008; Adair et al., 2009;
Masaki et al., 2010). In addition, the RNA sequence encoding the
first 62 aa of Core contains highly conserved structures including
two stem-loops that are important for RNA translation/replication
(McMullan et al., 2007). Domain II (aa∼120–170) is predicted to
form two alpha-helices that enable Core to associate with mem-
brane proteins and lipids. Domain II is involved in targeting of
Core to LDs. It has been proposed that domain II folding occurs in
a membrane environment and is critical for the folding of domain
I (Boulant et al., 2005). In addition, a cysteine residue at aa 128
of domain II creates a disulfide bond to produce a Core protein
dimer that is required for particle formation (Kushima et al., 2010).
Domain III, pertaining to∼20 residues at the C-terminal, is highly
hydrophobic and serves as a signal sequence for E1. Although little
is known about the molecular mechanisms governing assembly of
Core into nucleocapsids, comprehensive mutagenesis studies have
enabled identification of various aa residues which are essential
for HCV morphogenesis (Murray et al., 2007; Alsaleh et al., 2010;
Kopp et al., 2010).
INVOLVEMENT OF OTHER HCV PROTEINS IN ASSEMBLY
Two N-glycosylated envelope proteins E1 and E2 are exposed on
the surface of the virus as a heterodimer thatmediates viral attach-
ment to host-cell receptors and facilitates virus entry (Op De
Beeck et al., 2004; Vieyres et al., 2010). During their synthesis,
E1 and E2 assemble as non-covalent heterodimers. Ectodomains
of E1 and E2 are translocated inside the ER lumen and their
transmembrane domains are inserted in the membrane of this
compartment. E1 contains four to five N-linked glycans and E2
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HCV is characterized by high genome variability and is classified into the seven major 
genotypes or genetic groups 22. Most of the genotypes are further divided into a number of 
subtypes. In HCV infected individuals the HCV pool is present as a population of closely related 
but slightly different genetic variants or quasi-species. Such a population of distinct genetic 
variants of the same virus is formed due to a combination of several factors. One of them is an 
inability of the HCV RNA-dependent RNA-polymerase (NS5B protein) to perform a 
proofreading function, which results in a high mutation rate of approximately 1-3x10-3 
substitutions/site/year 23. Another factor is the high viral production rate (up to 1012 virions/day) 
in the infected host 24. The viral quasi-species pool is subject of permanent change during both 
acute and persistent infection and this process seams to play a very important role in HCV 
biology and pathogenesis 24-26. In particular, it should be mentioned that the existence of a 
swarm of quasi-species provides a basis for mechanisms by which HCV avoids the host immune 
surveillance. 
 
1.2 Characteristics and functions of HCV proteins 
Depending on the genotype of HCV the ORF consists of 9024 to 9111 nt and encodes at least 10 
proteins, including three structural proteins (C, E1, and E2), and seven nonstructural proteins 
(p7, NS2, NS3, NS4A, NS4B, NS5A. NS5B). The HCV polyprotein is processed by host 
cellular and viral proteases (Fig.1.1.). 
 
1.2.1 Core 
The first structural protein, the HCV core, is highly basic protein with RNA-binding capacity, 
which forms the viral capsid by multimerization. It is released as a precursor of 191 aa (23 kDa, 
P23), whereas the predominant mature core protein has a size of 21 kDa 27 and can be divided 
into three functional domains: the 120 aa N-terminal hydrophilic domain D1 is involved in RNA 
binding and mediates nuclear localization by three predicted nuclear localization signals (NLS) 
28-30 50 aa C-terminal hydrophobic domain D2 is responsible for the association of core protein 
with endoplasmic reticulum (ER) membranes, outer mitochondria membranes and lipid droplets 
30,31. The last ca. 20 aa of the core protein serve as a signal peptide for the downstream located 
E1 protein 32-34. Besides being involved in particle formation, the core protein interacts with 
multiple host cellular pathways and proteins with potentially important roles in the viral life 
cycle 35. In particular, the core protein transcriptionally up-regulates growth-related genes in 
Huh-7 cell 36. It also demonstrates pro- and anti-apoptotic effects 37-39, and was suggested to be 
involved in tissue-damage and progression of liver fibrosis 40. Furthermore, the core protein 
Introduction 
 
 
4 
might regulate the activity of cellular genes like c-myc and c-fos, and influence transcription of 
other viral promotors 41,42. In transgenic mice the expression of core induces the development of 
HCC, and by the induction of lipid droplet formation it may play a direct role in steatosis 
development 43-45.  
 
1.2.2 ARFP 
The alternate reading frame protein (ARFP) of approximately 160 aa., which seems to be a 
product of a frame shift in the N-terminal core region during polyprotein synthesis, has been 
described 46. Presence of this protein in natural HCV infection was confirmed by the detection of 
antibodies against ARFP in chronically infected patients. The role of ARFP during HCV 
lifecycle is still unknown, although, some indications of its contribution to viral persistence have 
been reported 47. 
 
1.2.3 E1/E2 
E1 and E2 are glycoproteins of the HCV viral envelope with sizes of 33 - 35 and 70 - 72 kDa, 
respectively, form noncovalent heterodimers 48 that are essential for viral fusion and entry 49,50. 
Classified as type I transmembrane glycoproteins, the E1 and E2 have N-terminal ectodomains 
of 160 and 334 aa, respectively, and contain up to 5 and 11 glycosylation sites, respectively, as 
well as numerous cysteine and proline residues, and short C-terminal transmembrane domains of 
approximately 30 aa 51,52. 
The E2 protein bears three hyper-variable regions with differences in the aa sequence of up to 80 
% between different HCV genotypes and even sometimes between isolates of the same virus 
strain 53. The hypervariable region 1 (HVRI) consists of the first N-terminal 27 aa of E2 and 
presumably contains a major HCV neutralizing epitope 54,55. Despite a high sequence variability 
of the HVRI, there is a conservation of aa at particular positions, as well as a preservation of 
physiochemical properties of aa residues at other positions 56. Overall, these findings suggest 
that both variability of the aa content and conservation of the molecular conformation of HVRI 
are important and reflect an essential role of HVRI in the viral life cycle 57,58. Thus, the 
variability of the HVRI seems to be a basis for the virus to escape from the host humoral 
immune response 57. The HVRI as a region with positively charged residues at particular 
sequence positions might interact with negatively charged molecules found on surfaces of host 
cells and thereby play a role in host cell recognition, attachment, tissue and cell compartment 
localization 49,57-59. The HVRI interacts with high-density lipoproteins (HDL) and scavenger 
receptor B type I (SR-BI) 60,61. Furthermore, the HVRI was found to modulate the binding of E2 
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to the CD81 receptor 62-64. E2 contains two further hypervariable regions: the hypervariable 
region 2 (HVR2) and the intergenotypic variable region (igVR). These regions are suggested to 
be involved in heterodimerization of E1 and E2, as well as in viral infectivity 65,66. 
Not much is known about functions of E1, except that it’s folding is dependent on the co-
expression of E2 67,68 and that the E1/E2 heterodimer is responsible for the first steps of HCV 
interaction with the host cell 69,70. Some data suggest that E1 might play a role in fusion of the 
virus with membranes inside the cytoplasm 69. 
 
1.2.4 P7 
The first nonstructural protein p7 with a size of 63 aa belongs to the viroporin family and might 
function as a calcium ion channel 71,72. It was shown to be essential for assembly and release of 
infectious particles, as mutations in the cytoplasmic loop of p7 suppressed infectivity in 
experiments on chimpanzee 73,74. 
 
1.2.5 NS2 
The NS2 protein with a size of 21 - 23 kDa is a non-glycosylated transmembrane protein bearing 
two internal signal sequences (aa 839 - 883 and aa 928 - 960) that mediate association with the 
ER membrane 75,76. In combination with the N-terminal part of the NS3 protein, NS2 forms the 
NS2-3 protease, which acts as a zinc-dependent metalloprotease and cleaves between NS2 and 
NS3 32,77,78. After auto-cleavage from NS3 the NS2 protein looses its catalytic activity and is 
directed to the proteasome for degradation. It was shown that NS2 is essential for the production 
of infectious virus particles 79. 
 
1.2.6 NS3/NS4A 
The NS3 protein with a size of 67 kDa is multifunctional protein with an N-terminal located 
serine protease domain and a C-terminal helicase/NTPase domain. The NS4A protein (54 aa) 
acts as an activity enhancing cofactor and forms a heterodimer with NS3, the NS3-NS4A 
protease, which is essential for the viral life cycle. The NS3-NS4A protease catalyzes the 
cleavage between NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B 80-82. It was shown 
that the NS3-NS4A protease interacts with different host cell pathway, like antagonizing the 
dsRNA-dependent interferon regulatory factor 3 (IRF-3) 83 or hampering the toll-like receptor 3 
signaling upstream of IRF-3 84. Thus, the NS3-NS4A protease is an important factor for the virus 
to counteract the host innate immune response. The C-terminal helicase/NTPase domain of NS3 
belongs to the helicase superfamily-2 and possesses several functions, like RNA binding, RNA 
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unwinding and RNA-stimulated NTPase activity 85,86. It was also suggested that the NS3 protein 
might be involved in development of hepatocellular carcinoma 87,88. 
 
1.2.7 NS4B 
The NS4B integral membrane protein with a size of 261 aa (27 kDa) is located at the ER 
membrane 89,90. As a part of the replicase complex the NS4B protein functions as an ER 
membrane anchor for the replication complex, thereby creating a site for viral genome synthesis 
91-93. Furthermore, NS4B is involved in the process of virus particle assembly and release 94. 
 
1.2.8 NS5A 
The phosphorylated zinc-metalloprotein NS5A with a size of 56 - 58 kDa is membrane 
associated and is essential for viral replication. It plays a role in formation of the viral replication 
complex and regulates host cellular pathways 95. Additionally, the NS5A protein is able to 
interact directly with the RNA-dependent RNA-polymerase NS5B and influence its activity by a 
mechanism that still needs to be clarified 96. 
 
1.2.9 NS5B 
The NS5B protein of 65 kDa is a tail-anchored membrane protein functioning as an RNA-
dependent RNA-polymerase (RdRp) 97-100. NS5B can interact with cellular factors as cyclophilin 
B, which is likely to regulate viral replication by influencing the RNA binding capacity of NS5B 
101. Many anti-HCV drugs target the RdRp-activity of NS5B 102-105. 
 
1.3 HCV life cycle 
1.3.1 Viral attachment and entry 
The interaction of HCV envelope proteins with host cellular heparan sulfate proteoglycans 
(HSPG) is thought to be the initial step in attachment of HCV to target followed by binding to 
another receptor/receptor complex with high affinity that mediates viral entry via clathrin-
dependent endocytosis 59,106. Several cellular molecules were identified as members of the 
receptor complex: the low density lipoprotein (LDL) receptor (LDLR), dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), and liver/lymph node-
specific intracellular adhesion molecule-3-grabbing non-integrin (L-SIGN), CD81, Scavenger 
receptor class B member 1 (SR-BI), claudin-1 and occludin-1 107,108. Figure 1.2 shows a model 
of cell receptors needed for successful infection of cells. 
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Fig.  1.2 Model of cell surface molecules essential for HCV entry 109. 
 
1.3.1.1 CD81 
The human CD81 molecule with a size of 25 kDa belongs to the tetraspanin or transmembrane 4 
superfamily. It is found at the surface of numerous cell types and is involved in pleiotropic 
activities such as cell adhesion, motility, metastasis, cell activation, and signal transduction 110. 
CD81 contains four hydrophobic transmembrane regions (TM1 - TM4) and two extracellular 
loop domains of 28 and 80 aa, respectively. The small extracellular loop (SEL) between TM1 
and TM2 is needed for optimal surface expression of the large extracellular loop (LEL) that is 
located between TM3 and TM4 and mediates binding of HCV by interactions with E2 111,112. 
Among different species the intracellular and transmembrane domains of CD81 are highly 
conserved, whereas the LEL is highly variable. The only species that can be infected by HCV 
are humans and chimpanzees, due to their similarities in the LEL of CD81 113,114. The human 
hepatoma cell lines HH29 and HepG2 lack the expression of CD81 and do not support HCV 
infection in cell culture. Their permissiveness to infection with HCV pseudo-particles (HVCpp) 
could be restored by transfection with and expression of human CD81. A reduced rate of viral 
infection was achieved through silencing of CD81 by CD81-specific small interfering RNA 
(siRNA) 115,116. The expression of human CD81 in murine fibroblasts was shown to be 
insufficient to support HCV entry and mice transgenic for human CD81 remained resistant to 
HCV infection 117,118. Inhibition of viral entry by anti-CD81 antibodies was suggested to occur at 
the post-binding step 119. These findings support the essential role of CD81 in the process of 
viral entry, but also indicate that other host cellular factors are needed to establish HCV 
infection. 
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1.3.1.2 SR-BI 
The scavenger receptor B type I (SR-BI) with a size of 82 kDa is a glycoprotein bearing a large 
extracellular loop that is anchored by C- and N-terminal transmembrane domains with short 
cytoplasmic tails, was shown to serve as another receptor for HCV E2 120,121. SR-BI is expressed 
at high levels in hepatocytes, in steroidogenic cells, as well as in human monocyte derived 
dendritic cells 120,122,123. Its physiological ligands are high-density lipoproteins (HDL) and low-
density lipoproteins (LDL), which are internalized after binding by clathrin-independent 
endocytosis that mediates the uptake of cholesterol and recycling 124. HDL was shown to 
enhance viral entry by a mechanism that depends on the physiological function of SR-BI in 
terms of lipid transport. The LEL was suggested to be responsible for binding of HCV through 
interaction with HVRI of HCV E2 and deletion of HVRI significantly reduced HCVpp 
infectivity 49,61,121,125. In a chimpanzee model, different HCV clones with deletion of the HVRI 
showed attenuated infectivity 126. Antibodies specific for SR-BI were shown to reduce but not 
completely block the binding of HCV to hepatocytes, indicating that other molecules are also 
involved in this process 127. 
 
1.3.1.3 Claudin-1 and occludin 
Recently, two tight-junction proteins claudin-1 (CLDN1) and occludin (OCLN) have been 
reported as two additional essential HCV entry factors 107. These proteins seem not to interact 
directly with HCV virions and, most probably, are involved in a late post-binding step. It was 
suggested that CLDN1 can interact with CD81 and that this interaction might be a crucial step in 
formation of the HCV receptor complex 128. Several cell lines were rendered susceptible to 
HCVpp and HCVcc entry through transient expression of CLDN1, whereas silencing of CLDN1 
by specific siRNA in permissive cells caused a significant reduction of HCV entry 129. Specific 
antibodies against CLDN1 were able to inhibit HCV entry by constraining the interaction 
between HCV E2 and CLDN1, as well as between CD81 and CLDN1 130.  Two other tight 
junction proteins, claudin-6 and claudin-9, are possibly also functioning as co-receptors for HCV 
131. The exact role of OCLN in the HCV entry mechanisms is not completely clear. 
 
1.3.1.4 EGFR and ephrin receptor A2 
More recently, two receptor tyrosine kinases, the epidermal growth factor receptor (EGFR) and 
the ephrin receptor A2, were identified to be required for HCV entry. These proteins may 
function as modulators of interactions between CD81 and CLDN1 132. 
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1.3.1.5 DC-SIGN and L-SIGN 
Different studies suggest that the dendritic cell-specific intercellular adhesion molecule-3-
grabbing nonintegrin (DC-SIGN) and the liver/lymph node-specific intercellular adhesion 
molecule-3 (I-CAM-3)-grabbing integrin (L-SIGN) could determine the tissue tropism of HCV 
and might play a role in viral pathogenesis 133-136. The type II integral membrane protein DC-
SIGN with a size of 44 kDa is highly expressed on myeloid dendritic cells and its interaction 
with ICAM-3 leads to activation of T-cells 137. L-SIGN with a 77 % sequence identity to DC-
SIGN is highly expressed at the cell surface of liver and lymph node endothelial cells, but not on 
DCs 138. It also shares functional similarities with DC-SIGN in its interaction with ICAM-3. One 
study with HCV pseudo-particles (HCVpp) showed rapid internalization upon interaction of 
HCV E2 with DC-SIGN and L-SIGN 139, whereas another did not report this 135. 
 
1.3.1.6 LDLR 
The low-density lipoprotein (LDL) receptor (LDLR) is a glycoprotein with a single 
transmembrane domain that is involved in the endocytic transport of lipoproteins, mainly 
cholesterol-rich LDLs 140. It was demonstrated that HCV virions complexed with LDL enter 
their target cells by utilizing the LDLR 141,142. Specific antibodies against LDLR or the addition 
of high levels of LDL were shown to inhibit HCV infection of hepatocytes in cell culture 143. 
 
1.3.2 HCV replication, particle assembly and release 
Cellular attachment and interaction of HCV with the receptor complex leads to endocytosis of 
the virus particles, and is followed by fusion of viral and endosomal membranes, in a pH-
dependent process, leading to the release of the viral genome to the cytoplasm of host cells 
8,144,145. The released viral RNA serves as mRNA for synthesis of the HCV polyprotein, as well 
as template for production of the negative RNA strand. The negative strand then acts itself as a 
template for synthesis of new positive-oriented viral RNAs. The new positive RNAs are 
subsequently used for synthesis of negative strands of RNA, which are either used for protein 
expression or for packaging into virions 97. HCV polyprotein synthesis is mediated by the HCV 
IRES in cap-independent manner through recruitment of several cellular proteins, like the 
eukaryotic initiation factors (eIF) 2, 3, and 5B, and viral proteins 146-148. Subsequently, a 
functional 80S ribosome complex is formed that initiates viral protein production. The processed 
HCV proteins are retained at the membrane of the endoplasmic reticulum (ER). As a 
consequence of HCV protein expression, the intracellular membranes are altered to form the 
„membranous web“, which is derived from ER membranes and represents the site of viral 
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replication 97,149. The viral particle assembly is initiated by interactions of HCV core protein with 
viral genomic RNA and seems to occur on lipid droplets (LDs), as core protein was shown to 
coat the surface of LDs 150. The HCV structural proteins were detected in the ER and Golgi 
apparatus, suggesting an important role of these cell organelles in the later maturation process 
151. The viral progeny virions might be released from host cells via the constitutive VLDL 
secretory pathway 152(Fig.1.3). 
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Fig.  1.3 Extracellular HCV virions interact with receptor molecules, 
 at the cell surface (1) and undergo receptor-mediated endocytosis (2). Following 
HCV glycoprotein-mediated membrane fusion, the virion’s nucleocapsid (which 
contains the viral RNA) is released into the cytoplasm (3). The genomic RNA is 
translated to generate a single large polyprotein that is processed into the 10 mature 
HCV proteins. The endoplasmic reticulum is modified by viral and cellular factors to 
form a membraneous web, which is the major site of viral RNA amplification (4). 
Six of the mature HCV proteins assist the replication of viral RNA via synthesis of 
positive strands (+) from a replicative intermediate negative RNA strand (-) template 
(5).A portion of this newly synthesized RNA is packaged into nucleocapsids and 
associated with the HCV glycoproteins, a process that leads to virion budding into 
the endoplasmic reticulum (6). During processing through the cellular secretory 
pathway the virions achieve maturation (7). Mature virions are released from the cell 
to complete the life cycle (8). 153 
 
Introduction 
 
 
12 
1.4 Antiviral immunity 
1.4.1 The innate immune response 
For HCV, as for many viruses, the innate immune responses, especially the induction of type I 
and III interferons (IFNs) are the first line of defense limiting viral replication and spread, thus 
contributing to control of viral infection 154,155. In the very early phase of infection the host 
innate immune response is triggered when infected cells recognize molecular signatures within 
the virus 155-157. These signatures, known as pathogen-associated molecular patterns (PAMPs), 
are recognized as „non-self“ by host pattern recognition receptors (PRRs). Engagement of the 
different PRRs, divided into the cytoplasmic retinoic inducible gene-I (RIG-I)-like receptors 
(RLRs) and Toll-like receptors (TLRs) depending on their sub-cellular localization, initiates a 
cascade of events that induces the expression of antiviral effector genes and production of 
interferons (IFNs), as well as a spectrum of inflammatory cytokines and chemokines 154,155. IFN-
α/β and IFN-λ induce the expression of more than 300 interferon-stimulated genes (ISGs) and 
their products have antiviral, anti-proliferative, and immuno-modulatory functions 155,158. The 
IFN-induced proteins include the protein kinase R (PKR), the dsRNA-specific adenosine 
deaminase I (ADARI), and the 2‘,5‘-oligoadenylate synthetase (OAS). PKR reduces the rate of 
HCV RNA translation by phosphorylation of the eukaryotic initiation factor 2 (eIF2). ADARI 
catalyzes the transformation of adenosine to inosine, thereby causing the accumulation of 
mutations inside the replicating viral RNA. OAS activates the latently expressed RNAse L, 
which subsequently catalyzes the degradation of cellular and viral RNA molecules. The list of 
identified products of the ISGs also includes several known broadly active regulators of antiviral 
signaling pathways such as the retinoic acid-inducible gene-I (RIG-I), the melanoma 
differentiation–associated protein 5 (Mda5), interferon regulatory factor 1 (IRF1), 2 (IRF2), and 
7 (IRF7), as well as a number of proteins with not yet well defined functions 155,158. In addition 
to the expression of ISGs type I IFNs influence the regulation of miRNAs, including those 
inhibiting HCV RNA replication and the proviral miR-122 155. Overall, the available data 
suggest that not a single but multiple factors participate in IFN-mediated inhibition of HCV 
replication and that only a well-concerted activity of all IFN-induced proteins and miRNAs is 
able to establish an antiviral state of the host cell. In the majority of infected individuals, 
however, the innate immune responses do not eliminate the invading virus, suggesting that type I 
IFNs alone are insufficient to completely control HCV replication in infected hepatocytes 155. 
 
Introduction 
 
 
13 
1.4.2 The humoral immune response 
For many years the progress towards understanding the role of the humoral immune response in 
HCV infection was hampered due to the absence of adequate experimental techniques for virus 
binding, entry and virus neutralization measurement 159. A breakthrough occurred after the 
development of the HCV pseudotype (HCVpp) system based on the usage of rhabdo- or 
retrovirus particles pseudotyped with HCV E1 and E2 glycoproteins 49,160,161. The most recent 
introduction of virus strains and recombinant viral genomes capable to replicate and form 
infectious particles in cell culture (HCVcc) provided a major new approach to study HCV 
interaction with human cells and neutralization potentials of antiviral antibodies, including 
human monoclonal antibodies directed against envelope proteins 159,162,163.  
Antibodies to both structural and nonstructural HCV proteins appear 7-8 weeks after onset of an 
acute infection and are preserved during the whole period of viral persistence 163-169. Most of the 
neutralizing antibodies (nAbs) seem to be directed against linear and conformational epitopes of 
E2 and, to a lesser extent, E1. Available data clearly indicate that the virus-specific humoral 
immune response plays an essential role in the control of HCV infection 159,162,163. This is 
supported by an experiment where passive transfer of an HCV-specific immunoglobulin to 
chimpanzees significantly delayed the super-infection of the animals, although complete 
prevention of super-infection was not achieved 170. Another study demonstrated a passive 
protection against HCV in a cohort of patients who received immunoglobulin preparations 
derived from HCV RNA-positive plasma 171. In immune-compromised patients, e.g. 
hypogammaglobulinemic patients, a rapid disease progression was observed, showing the 
potential important role for the humoral immune response of controlling the virus in the chronic 
phase 172. One should note, however, that some of these patients were able to eliminate the virus 
without the support of humoral response, suggesting a contribution of the cellular immune 
response to the control of the virus 173. Experiments with the HCVpp system have shown that a 
rapid induction of nAbs in the early phase of infection is associated with spontaneous viral 
clearance and that these antibodies demonstrate a broader cross-neutralization capacity. In 
contrast, patients, who developed a chronic infection, had only very low titers of nAbs or no 
antibodies during the acute phase of infection 174,175. Patients in the chronic stage of HCV 
infection usually show high titers of anti-E2 antibodies, but these are unable to clear the virus 
175. An impaired ability to cross-neutralize viral variants that rapidly emerged during acute 
infection may thus contribute to viral evasion from the neutralizing response in persistent HCV 
infection 175,176 
Antibodies directed against the HVRI seem to play a special role, as they exhibit a high virus 
isolate specificity. High concentrations of these antibodies are needed for effective neutralization 
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49,165,177-179,58. Some studies of HCV viral evolution in the acute phase of infection revealed an 
association between resolved infection and stability of the HVRI, whereas viral persistence was 
accompanied by remarkable sequence changes in the HVRI over time 57,180. Most recent data 
have shown that antibodies to HVRI play the major role in neutralization of virus spreading by 
cell-to-cell route but not of cell-free virus 181. 
 
1.4.3 The adaptive cellular immune response 
The successful clearance of HCV by the infected individual is associated with strong, multi-
specific and sustained CD4+ and CD8+ T-cell responses targeting the different HCV proteins 
182-189. Generally, T-cell responses can be detected 6 - 8 weeks after initial infection and correlate 
with hepatic inflammation. This delay of detectable T-cell response is rather due to a delayed 
induction than to an impaired recruitment of specific CD8+ T-cells to the site of infection, 
namely the liver 190. Once HCV infection is cleared, the specific CD4+ and CD8+ T-cell 
responses can be detected even after decades and sometimes they also outlast the specific 
humoral immune response 191. 
As a strong, multi-specific CD4+ T-cell response in acutely HCV infected patients is associated 
with a self-limiting course of infection the HCV-specific CD4+ T-cells contribute to viral 
clearance 184-186,192-194. Thus, CD4+ T-cell depletion in chimpanzees led to viral persistence after 
HCV infection and the appearance of CD8+ T-cell escape variants of the infecting strain 195. 
Additionally, particular HLA type II alleles were observed to be associated with the outcome of 
HCV infection. In heterogeneous cohorts, the HLA type II alleles DRB1*1101 and DQB1*0301 
seem to be protective, whereas in the well described Irish anti-D cohort the alleles DRB1*01, 
DRB1*0401, and DRB1*15 seem be associated with viral clearance 196,197. Epitopes of CD4+ T-
cells can be recognized by more than one HLA type II molecule, thus, these epitopes are 
restricted by several HLA type II molecules 159. Additionally, CD4+ T-cells producing IL-17 
have been detected in chronically infected patients, but their role during HCV infection is still 
unclear 198. 
In addition to CD4+ T-cells, HCV- specific CD8+ T-cells are recognized as a key contributor to 
HCV clearance 155. Thus, a robust CD8+ T-cells multi-specific response against HCV in the 
liver and peripheral blood was found to coincide with the onset of liver disease and viral 
clearance 182,183,187-189,199. Several HLA type I molecules, including the A03, A11, B27, B57 and 
Cw*01, were shown to be protective and associated with viral clearance, whereas the presence 
of allels B08 and Cw*04 correlated with HCV persistence 197,200-204. Recent experiments with the 
HCV replicons in vitro have demonstrated that the virus-specific CD8+ T-cells possess non-
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cytolytic effector functions mediated by IFN-γ and to a lesser extend cytolytic effector functions 
205. Furthermore, CD8+ T-cells restrained HCV replication in vivo, indicating them as the key 
effector cells for controlling HCV infection: the experimental depletion of CD8+ T-cells in HCV 
infected chimpanzees led to viral persistence until the CD8+ T-cell population was restored and 
HCV-specific CD8+ T-cell response became detectable 155,206.  
Taken together, the available data clearly indicate that HCV-specific CD4+ T-cells play an 
important role as key regulator cells, whereas virus-specific CD8+ T-cells play the essential role 
of the key effector cells during HCV infection 155. 
 
1.5 Mechanisms of immune evasion and viral persistence 
The majority of HCV infections (70-80 %) result in a virus persistence that might lead to such 
life-threatening sequelae as liver cirrhosis and hepatocellular carcinoma. The fact that HCV 
persistence is often observed in immuno-competent adults, perfectly capable of combating other 
infections, including those caused by hepatotropic pathogens, suggests that HCV developed 
several ways to circumvent the antiviral responses of the infected individual during coevolution 
with its host. The mechanisms by which HCV escapes from the immune surveillance are not 
fully understood. It is assumed that HCV has evolved several strategies to evade both the innate 
and adaptive immunity. As a result, HCV infected cells are not recognized and eliminated, and 
conditions for a long lasting persistent infection are created. 
 
1.5.1 Counteraction of the innate immune responses 
In cells infected with HCV the innate antiviral immune responses exerted through a complex 
multi-level network of cytokines and transcription factors play an essential role in elimination of 
the virus. There is accumulating evidence that HCV encoded proteins are engaged in pleiotropic 
interactions with many cellular macromolecules, thus interfering with the establishment of an 
IFN-induced antiviral state of the host cells 154,155,157,158. Indeed, the HCV NS3/4A protease was 
shown to cleave MAVS and TRIF, the central adaptor molecules in two IRF3 activating antiviral 
pathways, thereby interfering with the induction of the IFN response 207,208. Additionally, the 
NS3 protein can influence the RIG-1 and TLR3 signaling by competing with IRF3 for 
interaction with TBK1 206. Furthermore, HCV NS5A and core proteins have been reported to 
impair Jak-Stat signaling by affecting the phosphorylation step, which led to inhibition of the 
transcription of downstream ISGs 209,210. In addition, the expression of NS5A has been shown to 
induce IL8, which in turn attenuates the antiviral action of IFNs. The HCV proteins might also 
demonstrate their inhibitory activity by blocking the function of antiviral effector ISGs 155,157,158. 
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This is supported by the observation that both E2 and NS5A proteins bind to PKR and thereby 
block its effector function 155. 
Collectively, all available data provide evidence that several proteins encoded by HCV are 
involved in a wide variety of interactions with host cellular macromolecules causing 
deregulation of intracellular pathways. Most of these interactions are not yet recognized or fully 
characterized and it is still not clear, which of them are directly or indirectly related to the 
evasion from innate immune responses. Considering the complex interplay among multiple 
intracellular pathways it can be suggested that many viral proteins are implicated in the 
development of persistent infection. 
 
1.5.2 Evasion from the humoral immune response 
In the plasma of chronically infected patients high-titer cross-neutralizing antibodies are present 
169,171,175,176,211. Paradoxically, these antibodies are not able to control the infection, suggesting 
that HCV evolved some mechanisms to circumvent or to minimize the effects of the antiviral 
humoral immune response. 
It is well known that due to the fact that the virus-encoded RNA-polymerase lacks proofreading 
functions, the HCV population in every infected individual exists as a pool of quasispecies, 
closely related but phylogenetically different variants 26. These variants are changed over time 
due to a selective immune pressure driven by the host and this, in turn, might lead to the 
appearance of those virus variants that escape from antibody-mediated neutralization 49,169,211. 
Several studies on HCV sequence evolution in infected chimpanzees and humans support this 
hypothesis 162,169,180,212. Interestingly, the HVRI evolves more rapidly than other parts of the 
envelope proteins in vivo 162. It has been suggested that HVRI contains major neutralizing 
epitopes, and the ongoing variations of this fragment plays a major role in maintenance of 
persistent HCV infection 159,162. Of note, the HVRI was shown not to be essential for the HCV 
life cycle and HCV variants with deleted HVRI demonstrated infectivity, but in a diminished 
manner 213. Furthermore, HVRI deletion mutants showed a greatly increased susceptibility to 
nAbs in the HCVcc system 213,214. These data indicate that the HVRI shields the key nAb 
epitopes. Therefore, HVRI has been suggested to serve as an immunological decoy during 
infection by masking other functionally important but more conserved neutralizing epitopes 
159,162.  
In addition to HVRI, neutralizing epitopes have been identified in other regions of the E2 
protein, including those involved in interaction with the host cell receptors 162,215. Neutralizing 
antibodies to these epitopes seem to exert a continuous selective immune pressure on the 
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circulating virus variants, thereby contributing to HCV envelope gene evolution and emergence 
of viral escape variants 26,216,217. Of note is the fact that some of the viral mutations driven by 
nAbs are located outside the receptor binding sites. Nevertheless, due to allosteric effects these 
mutations might lead to complete escape from nAbs 162.  
Recently, one longitudinal study has provided an experimental proof of the viral escape 
hypothesis 169. The authors used a series of HCVpp bearing E1/E2 heterodimers of the HCV 
H77 strain obtained from a single patient at different time-points of infection. At each of the 
time-points patient-derived serum was able to cross-neutralize a wide spectrum of HCVpp and to 
neutralize those HCVpp variants with E1/E2 heterodimers from the preceding sampling dates 
but not the particles bearing the autologous E1/E2 heterodimer. Thus, this longitudinal analysis 
provided evidences for the continuous viral escape from emerging antibodies during the course 
of infection and suggested that humoral immune pressure is the major force for the sequence 
diversity of HVRI. However, it remains to be proven that this mechanism of escape from the 
humoral immune response is operative in all patients, including those with a long history of 
HCV persistence. 
Additionally, physical complexing of HCV virions with lipoproteins or their components, such 
as lipids and apolipoproteins provides another mechanism that might be involved in attenuation 
of the recognition of E2 neutralizing epitopes by nAb 162. Thus, it was shown that high-density 
lipoproteins (HDL) facilitate HCVpp infectivity and reduce the sensitivity of the particles to 
nAbs 60,159,218. The accessibility of the virus to neutralization might also be limited by the 
presence of a number of glycosylation sites in the envelope proteins 162. 
Recently, another mechanism supporting viral persistence has been presented 219,220. It was 
proposed that binding of antibodies to neutralizing epitopes located within the E2 region 
encompassing residues 412 to 423 can be inhibited by antibodies to non-neutralizing epitopes 
located in a region encompassing residues 434 to 446. However, such interference between 
neutralizing and non-neutralizing antibodies could not be confirmed in another report 221.  
Finally, it seems that the mode of infection of hepatocytes may influence the sensitivity of HCV 
to nAbs. HCV has recently been shown to spread not only by cell-free virions but also by cell-
to-cell transmission 181,222,223. At that, the cell-to-cell route seems to be resistant to both 
polyclonal and most monoclonal anti-HCV glycoprotein antibodies. Among the tested antiviral 
nAbs, those antibodies directed against HVRI demonstrated the highest efficacy in interfering 
with cell-to-cell transmission 181. 
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1.5.3 Evasion from the cellular immune response 
Although HCV-specific T-cell responses are detectable and virus-specific T-cells are enriched in 
the liver chronically infected patients, the virus cannot be eliminated from most of these 
individuals 159,224,225. Two mechanisms are suggested to be mainly responsible for the failure of 
virus-specific CD4+ and CD8+ T-cell responses during chronic HCV infection.  
 
1.5.3.1 Inhibition by cell surface molecules 
First, CD8+ T-cell dysfunction, e.g. the impairment to secrete IFNγ and/or to proliferate 
following a contact with antigen, is considered by many researchers as a major cause of viral 
persistence 226-228. Several pathways have been implicated in mechanisms of CD8+ T-cell 
exhaustion, although, the relative contribution of different inhibitory receptors for such 
dysfunction remain unclear 155,159. In chronically infected patients up-regulation of inhibitory 
molecules like PD-1 on HCV-specific CD8+ T-cells can be detected and intrahepatic CD8+ T-
cells expressing high amounts of PD-1 are prone to cell death 229-232. Antibody blockage of PDL-
1 lead to a partly restored proliferation capacity of these HCV-specific CD8+ T-cells after 
antigen contact, but not to the restoration of full functionality 229-232. The pathways other than 
PD-1 were also implicated. Thus, the application of antibodies directed against CTLA-4, another 
inhibitory molecule, lead to an increased antiviral CD8+ T-cell function 226. Additionally, 
another immune suppressive receptor, Tim-3, was detected on virus-specific CD8+ T-cells in 
chronic HCV infection and its blockade with specific antibodies also caused a restoration of 
CD8+ T-cell function 233-235. Recently, co-expression of the inhibitory receptors 2B4, KLRG1, 
and CD160 in addition to PD-1 was observed on virus-specific CD127-low CD8+ T-cells in 
chronic infection 236,237, suggesting that the cumulative or simultaneous effect of different 
pathways to HCV-specific CD8+ T-cell exhaustion is probable. Another factor leading to an 
exhausted phenotype of HCV-specific CD8+ T-cells might be the lack of CD4+ T-cell help. 
During chronic HCV infection CD4+ T-cells were shown to be functionally impaired, but not 
deleted, indicating an important role for CD4+ T-cell help in CD8+ T-cell dysfunction 155,238. 
Another possible cause of CD8+ T-cell dysfunction is the suppression of virus-specific CD8+ T-
cells by different subsets of regulatory T-cells. CD4+CD25+ regulatory T-cells have been found 
to be upregulated in chronically infected patients compared to those, who cleared the infection or 
uninfected controls. These cells suppress proliferation and IFN-γ secretion by HCV-specific 
CD8+ T-cells in vitro 209,239,240. Additionally, virus-specific regulatory CD8+ T-cells producing 
high amounts of IL-10 can also be detected in the liver during HCV infection 241. The 
suppressive effect of these cells on HCV-specific CD8+ T-cells could be abolished by antibodies 
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directed against IL-10 242. Myeloid suppressor cells might contribute to dysfunction of HCV-
specific CD8+ T-cells by production of reactive oxygen species 243. Finally, the specific 
microenvironment of the liver directs the immune response in the liver rather towards tolerance 
than to activation and liver dendritic cells, hepatic stellate cells, as well as liver sinusoidal 
endothelial cells play an important role in the induction of immune suppression 244. 
 
1.5.3.2 Immune escape by mutation of epitopes 
Another means of HCV evasion from T-cell responses is based on the immune escape 
mechanism 155,159. As has already been described in the current text, in each infected host the 
HCV population consists of permanently renewable pool of quasispecies. This pool provides a 
basis for a selection of virus variants under T-cell immune pressure. As a result, cells bearing the 
viral genomes with these escape mutations within the epitopes are not eliminated. Viral escape 
from CD8+ T-cell responses was detected in the acute phase of infection in individuals that 
developed a chronic course of infection, whereas this phenomenon could not be observed in 
patients that resolved HCV infection 183,245-247. Thus, the appearance of viral escape variants in 
the acute phase of HCV infection seems to correlate with viral persistence. After transmission of 
the mutated virus to a new host with different genetic background (different HLA types) a 
reversion of the escape mutation to the original one or to the consensus residue occurred in a 
large proportion of cases. Indeed, several studies showed that HCV reverts to the fittest 
sequence, probably the consensus one, if no sufficient selection pressure by T-cells is present 245. 
For example, an HLA-B08 associated escape mutation within the epitope reverted after 
transmission of the virus to an HLA-B08 negative subject 247. Furthermore, in the Irish anti-D 
cohort in the presence of the particular HLA-allele most of the amino acid substitutions inside 
known CD8+ T-cell epitopes were forward mutations, whereas in individuals lacking the 
particular HLA-allele reversions toward the consensus sequence could be observed 248. These 
data allowed to formulate the concept of a fitness cost and suggested that viral escape mutations 
often could reduce the virus fitness and lead to a reduced ability of the virus to replicate 249. 
Several recent studies on HLA allele-dependent HCV polymorphism allowed to identify putative 
new CD8+ T-cell epitopes on the assumption that CD8+ T-cell mediated pressure would select 
virus variants with escape mutation, thus leaving the corresponding specific footprints in viral 
sequences 203,250-253. Taken together, these data indicated that the CD8+ T-cell-mediated viral 
escape seems to be one of the major mechanisms of HCV persistence 155,159,254. 
In conclusion, it should be noted that many important questions regarding the escape mechanism 
are not completely answered yet. Thus, it looks like that so far, not all CD8+ T-cell epitopes 
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have been identified. The frequencies of the escape mutations in many epitopes as well as their 
fitness cost remain to be determined. Additionally, the contribution of the CD8+ T-cell-mediated 
immune pressure to evolution of the structural HCV proteins, first of all, of the envelope 
proteins, is not clear. One may expect, however, that further application of such approaches as 
population-based studies of special cohorts of HCV infected individuals (e.g. the single-source 
hepatitis C outbreaks) and their complementation with new experimental tools such as HCVcc 
system would allow to clarify these and many other unresolved issues 
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1.7 The goals and aims of the study 
As has been already shown in the previous chapter, intensive efforts by the scientific community 
during the last years led to a tremendous progress in our understanding of HCV biology and 
major characteristics of HCV infection. Nevertheless, many aspects of HCV research still 
remain far from being investigated in full details. The current study aims to fulfill some gaps in 
our knowledge, dealing with the evolution of viral genome at a population level, causal 
relationship between immune responses and viral evolution, and structural characteristics of 
viral proteins.  
 
The major goals of the current project were:  
 
• Analysis of the genetic heterogeneity of HCV isolates found in individuals infected by 
the HCV AD78 strain in a single source hepatitis C outbreak, which occurred in 1977-
1978 in the former German Democratic Republic.  
• Analysis of the HCV evolution at a population level and assessment of the contribution 
of CD8+ T-cell and humoral immune responses to evolution of HCV envelope protein 
E2 in a cohort of chronic hepatitis C patients infected in a single-source HCV outbreak.   
• Analysis of the isolate-specific features of the envelope protein E2 sequences of the HCV 
AD78 strain and of their influence on virus infectivity and replication. 
 
To reach these goals the following aims were formulated: 
 
• To create a sequence database (core-NS2 and NS4-NS5 genomic regions) for multiple 
isolates of the HCV AD78 strain obtained from individuals infected in a single-source 
outbreak of hepatitis C and from contaminated immunoglobulin batches.  To characterize 
the heterogeneity of the obtained sequences. 
• To apply this database in a special statistical approach to identify CD8+ T-cell epitopes 
under selective pressure associated with HLA class I. 
• To perform an experimental confirmation of putative novel epitopes. 
• To use the created consensus sequences of the HCV AD78 strain for generation of the 
AD78/JFH1 chimeric virus and to apply this newly developed HCVcc system for 
analysis of the fitness cost of the putative escape mutations identified in the current 
study. 
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• To analyze the frequency of synonymous and nonsynonymous mutations inside and 
outside of known and putative B- and T-cell epitope regions within the E2 protein from 
AD78 isolates obtained from the AD-cohort. 
• To apply the HCVcc system as well as the HCVpp–based approach for analysis of the 
influence of the additional amino acid tracks at the N-terminus of the E2 on virus 
infectivity and replication. 
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2 Material and Methods 
2.1 Material 
2.1.1 Human sera from chronically infected HCV patients 
Sera of patients infected with the AD78 strain were kindly provided by Prof. M. Wiese, St. 
Georg Hospital, Leipzig, Germany. Between August 1978 and March 1979, 14 HCV1b 
contaminated batches of anti-D immunoglobulin had been administered to 2867 women 
throughout East Germany for prophylaxis of Rhesus factor incompatibility. After application of 
the contaminated globulin, 93 % of the recipients developed an acute hepatitis C. After 25 years, 
86 % of the 1833 affected women still tested positive for hepatitis C virus antibodies and 46 % 
for HCV RNA 255. 
 
2.1.2 Chemicals 
Product Supplier 
β-mercaptoethanol Sigma-Aldrich Chemie GmbH 
Acrylamide 2 K solution AppliChem 
Agarose Eurogentec 
Ampicillin (50 µg/mL) Roche Diagnostics 
APS Roth 
Aqua Roti Phenol Roth 
Bromphenole-blue Sigma-Aldrich Chemie GmbH 
D-PBS Invitrogen 
Dimethyl sulfoxide Roth 
DMEM (4.5 g/L glucose) with L-glutamine Gibco 
EDTA solution (0.5 M), pH 8.0 AppliChem 
ECL Western Blotting Reagents GE Healthcare 
Ethanol Sigma-Aldrich Chemie GmbH 
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Product Supplier 
Ethidiumbromide Roth 
FACS-Clean Becton Dickinson 
FACS-Flow Becton Dickinson 
FACS-Rinse Becton Dickinson 
Fix Perm Becton Dickinson 
Fetal Calf Serum Biochrome 
Glycerol Sigma-Aldrich Chemie GmbH 
HEPES PAA Laboratories 
Isopropanol Roth 
Interleukin-2, human (10.000U) Roche Diagnostics 
Sodium-acetate (3 M), pH 5.5 Ambion 
Sodium-chloride  Merck 
Orange G Sigma-Aldrich Chemie GmbH 
Penicillin/Streptomycin  PAA Laboratories 
Perm Wash Becton Dickinson 
RPMI 1640 with L-glutamine PAA Laboratories 
Sodium dodecyl sulfate (SDS) AppliChem 
TBE ultra pure 10x Invitrogen 
TEMED Roth 
Triton X-100 Invitrogen 
Trypan Blue Gibco 
Trypsin-EDTA Gibco 
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Product Supplier 
X-Gal Bio Solve LTD 
 
2.1.3 Equipment 
Device Supplier 
Automatic incubator CO2 Kendro GmbH 
Balnce Vibra 
Bioimaging System (Gene genius) Syngene 
Centrifuge 3 LR Kendro GmbH 
Centrifuge 5804 Eppendorf 
Centrifuge 5414 R Eppendorf 
Centrifuge 5415 D Eppendorf 
Freezer Liebherr 
Fridge Liebherr 
FACS Calibur Becton Dickinson 
GeneAmp PCRSys 2400 Roche 
Gene Pulser II BioRad Laboratories 
Hera Safe Flow Kendro GmbH 
Heraeus CO2 Incubator Kendro GmbH 
Heraeus Megafuge 1.0 R Kendro GmbH 
Heraeus Multifuge 3 LR Kendro GmbH 
Inverted Microscope Carl Zeis 
Luminometer Promega 
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Device Supplier 
Microwave Panasonic 
Mini-Protean BioRad Laboratories 
Mr. Frosty Nalgene 
Pipette-Boy Eppendorf 
Pipettes Eppendorf 
Photometer Gene Quant Amersham Bioscience 
pH meter MP 220 Toledo 
Power-Pack BioRad Laboratories 
Rotary Mixer Oehmen 
Thermocycler Eppendorf 
Trans-Blot SD Transfer cell BioRad Laboratories 
Neubauer counting chamber  Superior Marienfeld Germany 
Ultracentrifuge Beckman Coulter 
UV transluminator FLX-20M MWG-Bio Tech 
 
2.1.4 Commercial kits 
Kit Supplier 
Bio-Rad Protein Assay Kit BioRad Laboratories 
CalPhos Mammalian Transfection Kit Clontech 
Expand High Fidelity PCR System Roche 
GoTag PCR System Promega 
GloLysis Buffer Promega 
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Kit Supplier 
One-step RT-PCR Kit Qiagen 
Qiagen Plasmid Maxi Kit Qiagen 
Qiagen Plasmid Mini Kit Qiagen 
RNeasy Kit Qiagen 
Qiaquick Gel Extraction Kit Qiagen 
Qiaquick PCR Purification Kit Qiagen 
QuikChange Lightning Site-Directed Mutagenesis Kit Stratagene 
TopoTA Cloning Kit Invitrogen 
MegaClear Kit Ambion 
MegaSkript T7 in vitro transcription Kit Ambion 
 
2.1.5 Plastic products 
Product Supplier 
FACS tubes Falcon/Becton Dickinson 
Dishes Greiner Bio-One 
Disposable syringes (10 mL) Sarstedt 
Gene Pulser Cuvette (0.4 cm) BioRad Laboratories 
Pipettes (2 mL, 5 mL, 10 mL, 25 mL) Greiner Bio-One 
Pipette tips (10 µL, 100 µL, 200 µL, 1000 µL) Starlab 
Reaction tubes (0.2 mL, 1.5 mL, 2 mL) Eppendorf 
V-bottom tubes (15 mL, 50 mL) Falcon/Becton Dickinson 
Cell-culture flasks Greiner Bio-One 
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Product Supplier 
Cell-culture plates Greiner Bio-One 
 
2.1.6 Membranes 
PVDF membrane Millipore, Germany 
 
2.1.7 Enzymes 
Enzyme Supplier 
GoTaq Polymerase Promega 
High Fidelity Polymerase Roche 
T4 DNA Ligase Roche 
Sal1 FastDigest (FD) Thermo Scientific 
Psi1 FD Thermo Scientific 
EcoRV FD Thermo Scientific 
Bcl1 FD Thermo Scientific 
Age1 FD Thermo Scientific 
Not1 Thermo Scientific 
Ssp1 Thermo Scientific 
Shrimp Alkaline Phosphatase Thermo Scientific 
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2.1.8 Oligonucleotides 
Primer 
designation Sequence Usage 
sv655s 5’-TAT AGA TAT CAT GGG GTA CAT 
TCC GCT CGT C-3’ 
Amplification of AD78 E1 (+ 
HVRI), with sv690as (57 °C), PCR 
II 
sv687s 5’-TTC GCC GAC CTC ATG GGG TAC-
3’ 
Amplification of AD78 E1 (+ 
HVRI), with sv828s (58 °C), PCR I 
sv690as 5’-GTT TTG AGA GAG TCA TTG CAG-
3’ 
Amplification of AD78 E1 (+ 
HVRI), with sv655s (57 °C), PCR 
II 
sv692s 5’-GCC TCG CCT ACT ATT CCA TG-3’ Amplification of AD78 E2, with 
sv1104as (57 °C), PCR II 
sv828as 5’-AGA ACA GMG CGG CAA KRA 
ACC-3’ 
Amplification of AD78 E1 (+ 
HVRI), with sv687s (58 °C), RT 
and PCR I 
sv980as 5’-GCT GCC GTT GGT GTT TAT AAG 
CTG-3’ 
Anti-sense primer for insertion of 
additional aa tracks N-terminal of 
HVR1 (AD78 variants A and B), 
HCVpp 
sv1019s 5’-TT GCT GGC GTC GAC GGC CCC 
ACC CGC ACG ATA GG-3’ 
Deletion of additional aa tracks N-
terminal of HVR1 (AD78 variant 
B) with sv980as, HCVpp 
sv1020s 5’-TT GCT GGC GTC GAC GGC CGT 
GGA GGT GGA CCC ACC CGC ACG 
ATA-3’ 
Insertion of additional aa track 
“RGGG” N-terminal of HVR1 
(AD78 variant B) with sv980as, 
HCVpp 
sv1021s 5’-TT GCT GGC GTC GAC GGC TCA 
CCC ACC CGC ACG ATA GG-3’ 
Insertion of additional aa track “S” 
N-terminal of HVR1 (AD78 variant 
B) with sv980as, HCVpp 
sv1022s 5’-TT GCT GCC GTC GAC GGC ACG 
TCA TGGG CCC ACC CGC ACG ATA 
GG-3’ 
Insertion of additional aa track 
“TSW” N-terminal of HVR1 
(AD78 variant B) with sv980as, 
HCVpp 
sv1023s 5’- TT GCT GCC GTC GAC GGC ATG 
TCA GGA CCC ACC CGC ACG ATA 
GG-3’ 
Insertion of additional aa track 
“MSG” N-terminal of HVR1 
(AD78 variant B), HCVpp 
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Primer 
designation Sequence Usage 
sv1024 5’- TT GCT GCC GTC GAC GGC GCT 
TCA GCA CCC ACC CGC ACG ATA 
GG-3’ 
Insertion of additional aa track 
“ASA” N-terminal of HVR1 
(AD78 variant B) with sv980as, 
HCVpp 
sv1025s 5’- TT GCT GCC GTC GAC GGC GAC 
AAC GAC AAC CCC ACC CGC ACG 
ATA GG-3’ 
Insertion of additional aa track 
“DNDN” N-terminal of HVR1 
(AD78 variant B) with sv980as, 
HCVpp 
sv1026s 5’- TT GCT GCC GTC GAC GGC CGT 
GGA GGT GGC GGA GGT GGT GGC 
GGC GGA CCC ACC CGC ACG ATA 
GG-3’ 
Insertion of additional aa track 
“RGGGGGGGGG” N-terminal of 
HVR1 (AD78 variant A) with 
sv980as, HCVpp 
sv1027s 5’- TT GCT GCC GTC GAC GGC CGT 
GGA GGT GGC GGA GGC GGA GGC 
CCC ACC CGC ACG ATA GG-3’ 
Insertion of additional aa track 
“RGGGGGG” N-terminal of 
HVR1 (AD78 variant B) with 
sv980as, HCVpp 
sv1032s 5’-CTG CCG TTG GTG TTG ATC AGT 
TGG ATG TTC-3’ 
Insertion of additional aa track 
“RGGG” N-terminal of HVR1 
(H77/JFH1) with sv980as, HCVcc 
sv1033as 5’-CTG CCG TTG GTG TTG ATC AGT 
TGG ATG TTG-3’ 
Anti-sense primer for insertion of 
additional aa track “RGGG” N-
terminal of HVR1 (H77/JFH1) with 
sv1043s, HCVcc and sequencing of 
E1/E2 junction 
sv1043s 5’-GCC GGC GTC GAC GCG CGT GGA 
GGT GGA GAA ACC CAC GTC ACC-3’ 
Insertion of additional aa track 
“RGGG” N-terminal of HVR1 
(H77/JFH1) WITH sv1033as, 
HCVcc 
sv1050s 5’-CTT TGC TGG CGT CGA CGG  CAC 
CAC CCG CAC GAT AGG G-3’ 
SDM of 1st position of HVR1, 
AD78 variant B, HCVpp 
sv1051as 5’-CCC TAT CGT GCG GGT GGT GCC 
GTC GAC GCC AGC AAA G-3’ 
SDM of 1st position of HVR1, 
AD78 variant B, HCVpp 
sv1055s 5’-TAT CCT RTT GCT CTT CCT TCT C-
3’ 
Amplification of AD78 p7-NS2, 
with sv1056as, PCR II and 
sequencing 
sv1056as 5’-TGA TGA TAC AGC CAA GYA 
GGC-3’ 
Amplification of AD78 p7-NS2, 
with sv1055s, PCR II and 
sequencing 
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Primer 
designation Sequence Usage 
sv1057s 5’-GGT RTA GGG TCA GTG CTC GTC 
TC-3’ 
Amplification of AD78 p7-NS2, 
with sv1058as, PCR I 
sv1058as 5’-GAC TRG TGA TGA TAC AGC CAA 
G-3’ 
Amplification of AD78 p7-NS2, 
with sv1057s, RT and PCR I 
sv1059as 5’-CAG CAA AGC CAA GAG GAA 
GAT AG-3’ 
Amplification of AD78 core, with 
sv1060s, RT and PCR I 
sv1060s 5’-GGG GCG ACA CTC CAC CAT AGA 
TC-3’ 
Amplification of AD78 core, with 
sv1059as, PCR I 
sv1061s 5’-TCC ACC ATA GAT CAC TCC CCT 
GTG-3’ 
Amplification of AD78 core, with 
sv1062as, PCR II 
sv1062as 5’-AGA GGA AGA TAG AGA AAG 
AGC AAC C-3’ 
Amplification of AD78 core, with 
sv1061s, PCR II and sequencing 
sv1067s 5’-GAT ACT GCC CTG TTC CTT CAC-
3’ 
Amplification of AD78 E2-p7 from 
globulins with sv1068as, PCR II 
sv1068as 5’-CTT TAT AGT ATG GTG ACA AGG 
TC-3’ 
Amplification of AD78 E2-p7 from 
globulins with sv1067s, PCR II 
sv1069s 5’-CTA CAA CAG AGT GGC AGA 
TAC-3’ 
Amplification of AD78 E2-p7 from 
globulins with sv1070as, PCR I 
sv1070as 5’-ATA TGA GCT TAG CGA GGA 
ACA-3’ 
Amplification of AD78 E2-p7 from 
globulins with sv1069s, PCR I 
sv1071as 
 
5’-GCC GCA TTG AGG ACC ACC 
AGG-3’ 
Specific amplification of AD78 
variant C E2 with sv1072s, PCR I 
sv1072s 5’-TGA TGA ATT GGT CAC CTA CAA-
3’ 
Specific amplification of AD78 
variant C E2 with sv1071as, PCR I 
sv1073as 5’-ATC AGC AGC ATC ATC CAC AAG-
3’ 
Specific amplification of AD78 
variant C E2 with sv1074s, PCR II 
sv1074s 5’-GTG GTA TCG CAG TTA CTC CGG-
3’ 
Specific amplification of AD78 
variant C E2 with sv1073as, PCR II 
sv1075s 5’-AAG CTG TCG RGG ACA TGG TG-
3’ 
Amplification of AD78 E2-p7 from 
patients with sv1070as, PCR I 
sv1076s 5’-TAT TCC ATG GTG GGG AAC TGG-
3’ 
Amplification of AD78 E2-p7 from 
patients with sv1068as, PCR II 
sv1080as 5’-GCC GCG AGC GTG GGG GTG 
AGC-3’ 
Amplification of AD78 core from 
patients with sv1081s, PCR I 
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Primer 
designation Sequence Usage 
sv1081s 5’-GAT CAA CCC GCT CAA TGC CTG-
3’ 
Amplification of AD78 core from 
patients with sv1080as, PCR I 
sv1082as 5’-CCA GCA GCG AGA GGA GTT 
GTC-3’ 
Amplification of AD78 core from 
patients with sv1083s, PCR II 
sv1083s 5’-TAG CCG AGT AGT GTT GGG TC-3’ Amplification of AD78 core from 
patients with sv1082as, PCR II 
sv1102s 5’-AAG CTG TCR TGG ACA TGG TGG-
3’ 
AD78 E2, with sv1103as (59 °C), 
PCR I 
sv1103as 5’-GCA GCA CAG AAG AAC ACA 
AGG-3’ 
AD78 E2, with sv1102s (59 °C), 
RT and PCR I 
sv1104as 5’-CAG AAG AAC ACA AGG AAG 
GAG-3’ 
AD78 E2, with sv692s (57 °C), 
PCR II 
sv1153s 5’-CGG AAC CGG TGA GTA CAC CG-
3’ 
Amplification of core-E2 from 
H77/JFH1 with sv1154as 
sv1154as 5’-CAT CGC GGC CGC CGC G-3’ Amplification of core-E2 from 
H77/JFH1 with sv1153s 
sv1155s 5‘-ARC AGG CAG GAG ACA ACT TC-
3‘ 
Amplification of AD78 NS3-NS5 
fragment A, with sv1164as (58 °C), 
PCR II  
sv1159s 5‘-ACT GGA TAT GCA CGG TGT TG-3‘ Amplification of AD78 NS3-NS5 
fragment B, with sv1160as (58 °C), 
RT  
sv1160as 5‘-TCC CCC GGC TCY CCC TCA AG-3‘ Amplification of AD78 NS3-NS5 
fragment B, with sv1159s (58 °C), 
RT  
sv1161s 5‘-CAG TCC AAR CTC YTG CCG CG-3‘ Amplification of AD78 NS3-NS5 
fragment B, with sv1162as (58 °C), 
PCR II 
sv1162as 5‘-CTC AAG RGG RGG CAT GGA GG-
3‘ 
Amplification of AD78 NS3-NS5 
fragment B, with sv1161s (58 °C), 
PCR II 
sv1163s 5‘-CCC AGA CYA ARC AGG CAG GR-
3‘ 
Amplification of AD78 NS3-NS5 
fragment A, with sv1164as (58 °C), 
RT  
sv1164as 5‘-CCT CAT GGA ACC RTT YTT GAC-
3‘ 
Amplification of AD78 NS3-NS5 
fragment A, with sv1163s (58 °C), 
RT  
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Primer 
designation Sequence Usage 
sv1182s 5’-CCG CGC AGG GGC CCT AAA TTG 
GGT GTG CGC-3’ 
SDM H77/JFH1: core R43K, with 
sv1183as 
sv1183as 5’-GCG CAC ACC CAA TTT AGG GCC 
CCT GCG CGG-3’ 
SDM H77/JFH1: core R43K, with 
sv1182s 
sv1184s 5’-CCT CTT GGA GGC GTT GCC AGG 
GCC CTG-3’ 
SDM H77/JFH1: core H153Q, with 
sv1185as 
sv1185as 5’-CAG GGC CCT GGC AAC GCC TCC 
AAG AGG-3’ 
SDM H77/JFH1: core H153Q, with 
sv1184s 
sv1202s 5’-CCG CGC AGG GGC CCC AAG TTG 
GGT GTG CGC-3’ 
SDM AD78/JFH1 variant A: core 
R43K, with sv1203as 
sv1203as 5’-GCG CAC ACC CAA CTT GGG GCC 
CCT GCG CGG-3’ 
SDM AD78/JFH1 variant A: core 
R43K, with sv1202s 
sv1204s 5’-CCT CTA GGG GGT GTT GCC AGG 
GCC CTG-3’ 
SDM AD78/JFH1 variant A: core 
H153Q, with sv1205as 
sv1205as 5’-CAG GGC CCT GGC AAC ACC CCC 
TAG AGG-3’ 
SDM AD78/JFH1 variant A: core 
H153Q, with sv1204s 
sv1206s 5’-C AGG CCG CCG GGG GGC AAC 
TGG TT-3’ 
SDM AD78/JFH1 variant A: E2 
Q546G, with sv1207as 
sv1207as 5’-AA CCA GTT GCC CCC CGG CGG 
CCT G-3’ 
SDM AD78/JFH1 variant A: E2 
Q546G, with sv1206s 
sv1208s 5’-C AGG CCG CCG GGC AAC TGG 
TT-3’ 
SDM AD78/JFH1 variant A: E2 
Q546A, with sv1209as 
sv1209as 5’-AA CCA GTT GCC CCG CGG CGG 
CCT G-3’ 
SDM AD78/JFH1 variant A: E2 
Q546A, with sv1208s 
sv1210s 5’-C AGG CCG GCG GGC AAC TGG 
TT-3’ 
SDM AD78/JFH1 variant A: E2 
Q546R, with sv1211as 
sv1211as 5’-AA CCA GTT GCC CGC CGG CGG 
CCT G-3’ 
SDM AD78/JFH1 variant A: E2 
Q546R, with sv1210s 
sv1214s 5’-CA GAG TGG CAG GTA CTG CCC 
TGT TC-3’ 
SDM AD78/JFH1 variant A: E2 
I674V, with sv1215as 
sv1215as 5’-GA ACA GGG CAG TAC CTG CCA 
CTC TG-3’ 
SDM AD78/JFH1 variant A: E2 
I674V, with sv1214s 
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2.1.9 Plasmids 
2.1.9.1 Commercial plasmids 
The pCR4 Topo plasmid (Invitrogen, Germany) was routinely used for cloning of PCR products. 
 
2.1.9.2 Plasmid containing the envelope genes of HCV AD78 infected patients 
The phCMV-IRES plasmid (5520 bp) was used for expression of the E1 and E2 proteins of 
HCV. This plasmid contains the IRES of EMCV that drives the translation of the HCV envelope 
genes. The inserted envelope protein genes were obtained during the amplification of HCV 
sequences from serum samples of AD78 patients collected at different time points. The 
generated set of plasmids was used for transfection of 293T cells in order to produce the HCV 
E1/E2 heterodimer for the generation of HCVpp. 
 
Fig.  2.1 Plasmid containing the envelope genes of HCV AD78 infected patients (var. A) 
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Fig.  2.2 Plasmid containing the envelope genes of HCV AD78 infected patients (var. B) 
 
2.1.9.3 Plasmid containing HIV-Gag, Pol genes 
The lentiviral vector pCMV delta R8.2 (8128) has been obtained from Addgene (USA). This 
plasmid expresses the HIV Gag and Pol proteins in 293T cells and was used for production of 
HCVpp. 
 
2.1.9.4 Plasmid containing the luciferase reporter gene 
The HPPT-EF1α- Luc HIV-1-based transfer vector contains the EF1 internal promoter, which 
drives the expression of Luc (luciferase reporter gene) gene. The plasmid was used for 
generation of HCVpp in 293T cells. 
 
2.1.9.5 Plasmids for production of HCVcc 
The AD78/JFH1 and H77/JFH1 plasmids were linearized and subsequently used for in vitro 
RNA transcription to produce full length HCV RNA for electroporation. 
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Fig.  2.3 Plasmids for production of HCVcc (AD78/JFH1) 
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Fig.  2.4 Plasmids for production of HCVcc (H77/JFH1) 
 
2.1.10  Buffers and Solutions 
DNA-loading buffer 5.5 mM Orange G 
1.2 M Saccharose 
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Lysis buffer (SDS-PAGE) 0.5 M Tris, pH 6.6 
1 % Glycerol 
10% SDS 
5 % 2-Mercaptoethanol 
0.05 % Bromphenole-blue 
 
Cytomix 120 mM KCl 
0.15 mM CaCl2 
10 mM K2HPO4/KH2PO4 (pH 7.6) 
25 mM HEPES (1 M stock solution, Gibco cell culture grade) 
2 mM EGTA 
5 mM MgCl2 
pH 7.6 (with KOH) 
 
cell lysis buffer  20 mM Tris HCL, pH 8.0 
137 mM NaCl 
10% Glycerol 
1 % Triton-X 100 
2 mM EDTA 
add H2O dest. to 100 % 
 
PBS 155 mM NaCl 
3 mM Na2HPO4 
1 mM KH2PO4 
pH 7.4 
 
4x SDS loading buffer 10 % Glycerine 
4 % SDS 
125 mM Tris, pH 6.8 
10 % 2-Mercaptoethanol 
0.02 % Bromphenole-blue 
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5x DNA loading buffer 50 % Glycerine 
20 mM Tris, pH 8.0 
50 mM EDTA, pH 8.0 
0.025 % Bromphenole-blue 
0.025 % Xylenecyanole 
 
10x TBE buffer 108 g Tris base 
55 g Boric acid  
0.5 M EDTA, pH 8.0 
 
Blocking buffer 
(immunostaining) 
1 % BSA 
0.2 % skimmed milk powder 
0.2 % sodium-acetate 
PBS 
 
non-denaturing lysis buffer 4 mL 0.5 M Tris-HCL, pH 8.0 
0.8 g NaCl 
10 mL Glycerol 
1 mL Triton-X 100 
0.4 mL EDTA solution (0.5 %) 
H2O 
 
40 % PEG solution 
(precipitation of HCVcc) 
40 g PEG 8000 
100 mL sterile PBS 
 
2.1.11  Antibodies 
2.1.11.1 Primary Antibodies 
Mouse mAb CET-3 was kindly provided by Prof. Chang-Yuli Kong (South Korea) 
Mouse mAb 9E10 was kindly provided by Prof. Charles Rice (USA) 
APC mouse anti-human CD8, Becton Dickinson 
FITC conjugated anti human IFNγ, eBioscience 
PE mouse anti-human CD4, Becton Dickinson 
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α-CD28/CD49d, Becton Dickinson 
 
2.1.11.2 Secondary Antibodies 
Goat-α-mouse IgG, peroxidase conjugated (A4416), Sigma 
Rabbit-α-mouse IgG and IgM, peroxidase conjugated, Dianova 
 
2.1.12  Medium for culture of E.coli 
LB Agar 25 g LB-Agar powder  
1 L dH2O 
 
LB Medium 25 g LB-Medium powder 
1L dH2O 
 
Both media were completed to 1000 mL with bi-distilled water and sterilized by autoclaving for 
15 minutes at 121 °C. Ampicillin was added to each medium at a final concentration of 100 
µg/mL. 
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2.1.13  Bacteria strains 
Strain Genotype Supplier 
TOP10 F- mcrA Δ(mrr -hsdRMSmcrBC) 
φ80lacZΔM15ΔlacX74 nupG recA1 
araD139 Δ(ara-leu)7697 galE15 galK16 
rpsL(StrR) endA1 λ- 
Invitrogen 
XL10-Gold endA1 glnV44 recA1 thi-1 gyrA96 
relA1 lac Hte(mcrA)183 
Δ(mcrCBhsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15 Tn10(TetR Amy CmR)] 
Stratagene 
DH5α supE44 ∆lacU169 (φ80lacZ∆M15) 
hsdR17 recA1 endA1 gyrA96thi-1 relA1 
Invitrogen 
Dam- ara-14 leuB6 fhuA31 lacY1 tsx78 
glnV44 galK2 galT22 mcrA dcm-6 
hisG4 rfbD1 
R(zgb210::Tn10) TetSendA1 
rspL136 (StrR) dam13::Tn9 (CamR) xylA
-5 mtl-1 thi-1 mcrB1 hsdR2 
 
New England Biolabs 
 
2.1.14  Eucaryotic cell lines 
2.1.14.1 Human hepatoma cell line Huh7.5 
Huh7.5 cells are a sub-line derived from Huh7 hepatoma cells (Blight et al., 2002). This sub-line 
was established by “curing” a cell clone containing a Con1 subgenomic replicon by prolonged 
treatment with alpha-interferon. The receptors, important for the initiation of virus entry, are 
expressed on the viral surface and, therefore, these cells can be used for studying virus entry. 
 
2.1.14.2 Human Embryonic Kidney 293T cells 
293T cells are an important variant of the HEK 293 cells. This cell line bears the SV40 large T-
antigen that allows episomal replication of transfected plasmids containing the SV40 origin of 
replication. In the current study 293T cells were used for generation of HCVpp. 
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2.1.14.3 Human cryo-conserved peripheral-blood monocytes (PBMCs) 
Patient (in most cases drug users) derived PBMCs, patients were HLA-typed and PBMCs were 
cryo-conserved. These cells were used for in vitro stimulation of CD8+ T-cells with short 
peptides (see section 2.2.3.5). 
 
2.1.15  Culture medium for Huh7.5 cells 
DMEM 500 mL 
FCS 10 % 
Non-essential amino acids 1 % 
HEPES 1 % 
Penicillin/Streptomycin 1 % 
 
2.1.16  Culture medium for HEK 293T cells 
DMEM 500 mL 
FCS 10 % 
Penicillin/Streptomycin 1 % 
 
2.1.17  Culture medium for human PBMCs 
RPMI 1640 500 mL 
FCS 10 % 
HEPES 1 % 
Penicillin/Streptomycin 1 % 
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2.1.18  Peptides 
Peptide 
designation Sequence HLA-specificity 
ADP01 APLGGAARALAHGVR core B51, wt 1 
ADP02 GAARALAHGVRVLED core B51, wt 2 
ADP03 GPKLGVRAT core B07, mutant 1 
ADP04 GPSLGVRAT core B07, mutant 2 
ADP05 GPTLGVRAT core B07, mutant 3 
ADP06 KLGVRATRK core A03, mutant 
ADP07 EVRNVSGVY E1 A26, wt 
ADP08 PASAYEVRNVSGVYH E1 B38, wt 1 
ADP09 YEVRNVSGVYHVTND E1 B38, wt 2 
ADP10 RMASCRPIDKF E2 B57, wt 
ADP11 NTRPPQGNW E2 B57, wt 
ADP12 NTRPPAGNW E2 B57, mutant 1 
ADP13 NTRPPRGNW E2 B57, mutant 2 
ADP14 NTRPPGGNW E2 B57, mutant 3 
ADP15 LLLSTTEWQI E2 A2402, wt 
ADP16 LLLSTTEWQV E2 A2402, mutant 1 
ADP17 VLPCSFTTL E2 A2402, mutant 2 
ADP18 TPLRDWAHAGLRDLA NS2 A01/B08, wt 
ADP19 RDWAHAGL wt NS2 B08, motif 
ADP20 TPLRDWAHAGL wt NS2 B08, truncated 1 
ADP21 RDWAHAGLRDL wt NS2 B08, truncated 2 
ADP22 DWAHAGLRDLA wt NS2 B08, truncated 3 
ADP23 RALAHGVRV core B51 motif 
ADP24 GAARALAHGVRV core B51 motif, shift left 
ADP25 RALAHGVRVLED core B51 motif, shift right 
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2.1.19  Used Software 
FigTree v1.2.2 http://tree.bio.ed.ac.uk/software/figtree/ 
FlowJo 7.6 Tree Star, Inc. 1997-2008 
GraphPad Prism GraphPad Software, Inc. 
HCV Sequence Database http://hcv.lanl.gov/ 
Mac OS X Macintosh 
iWork Macintosh 
MHC-I-binding-prediction http://tools.immuneepitope.org/analyze/html/ 
NCBI Homepage http://www.ncbi.nlm.nih.gov/ 
NEBcutter V2.0 http://tools.neb.com/NEBcutter2/index.php 
R-Programm http://www.R-project.org 
Se-Al v2.0a11 Carbon Sequence Alignment  
Editor v2.0a11 © 1996-2002 Andrew Rambaut 
SISA The Fisher exact test http://www.quantitativeskills.com/sisa/index.ht
ml 
SNAP-Programm synonymous-nonsynonymous analysis program 
(http://hcv.lanl.gov/) 
VectorNTI Sequence Analysis Software 
 
2.2 Methods 
2.2.1 Procaryotic Cells 
2.2.1.1 Transformation of E.coli 
Transformation of bacterial cells was performed according to the manufacturer’s instructions. In 
brief, bacterial cells (Top10 cells, DH5α, dam- or XL10-Gold cells) frozen at -80 °C were 
thawed on ice. Two micro-liters of 2-Mercaptoethanol were added to 45 µL of XL10-Gold cells 
aliquot and incubated for 10 min on ice. Top10 cells were used without addition of 
mercaptoethanol. No more than 10 % by volume of the plasmid DNA was added to the aliquot 
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of bacterial cells. This mixture was incubated on ice for 30 minutes. To improve DNA 
absorption by bacteria, a heat shock for 30 sec. at 42 °C followed by a subsequent incubation on 
ice for 5 min was performed. After addition of 250 µL LB-medium a mixture was incubated on a 
shaker for 2 hours at 37 °C. Using a sterile spatula the complete mixture was spread over an LB-
agar plate containing a selective antibiotic. The plates were incubated overnight at 37 °C. 
 
2.2.1.2 Plasmid DNA preparation using commercial kits 
One bacterial colony was picked up from the LB agar plate, using a sterile pipette tip and 
transferred into the flask with LB-medium containing the ampicillin (5 - 10 mL of medium for 
minipreps, 100 - 250 mL- for maxipreps). The bacteria culture was incubated overnight on a 
shaker at 37 °C. The culture was centrifuged at 5000 rpm for 15 min and cells were washed once 
with PBS. The DNA was extracted using the Qiaprep kits (Qiagen), according to the 
manufacturer’s protocol. DNA was quantified by spectrophotometry at 260 nm and the size of 
the plasmid was checked using the electrophoresis in agarose gel. 
 
2.2.2 Molecular Biological Methods  
2.2.2.1 RNA-Extraction from human sera 
HCV RNA was extracted from patients’ sera using the High Pure Viral RNA Kit (Roche) 
according to the manufacturer’s instructions. In brief, 200 µL serum was mixed with the Binding 
Buffer supplemented with Poly (A), transferred into a filter mini-column, and centrifuged for 30 
sec at 8000 x g. Afterwards, 500 µL Inhibitor Removal Buffer was added to the upper reservoir 
followed by centrifugation for 1 min at 8000 x g. The column was washed 2 times with 450 µL 
Wash Buffer. Viral RNA was eluted in 50 µL of Elution Buffer and directly used in the reverse 
transcription reaction or kept at -80 °C. 
 
2.2.2.2 Reverse-Transcription 
HCV RNA isolated from patient’s sera was reverse transcribed into cDNA using the 
Thermoscript kit (Invitrogen) according to the following procedure: 
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RT reaction mix I  
Primer (50 pmol/µL) 1 µL 
dNTPs (5 mM) 2 µL 
RNA 5 µL 
RNAse free water 5 µL 
Final volume 13 µL 
 
The RNA in Mix I was denatured for 5 min at 65 °C and directly cooled down on ice. 
 
RT reaction mix II  
5 x cDNA synthesis buffer 4 µL 
0.1 M DTT 1 µL 
RNAse Out (20 U) 1 µL 
RNAse free water 1 µL 
Final volume 7 µL 
 
Mix II was added to Mix I to a final volume of 20 µL and incubated for 1 h at 50 °C, followed 
by additional incubation step (5 min at 85 °C). Five µL of generated cDNA was used for PCR 1. 
 
2.2.2.3 Side-directed mutagenesis (SDM) 
Quick-Change Lightning site-directed mutagenesis kit (Stratagene) was used to introduce single 
point mutations into the plasmid sequences. In this technique two complementary mutagenic 
primers, containing the desired nucleotide are used to amplify the entire plasmid. The non-
strand-displacing action of the Pfu Ultra HF DNA Polymerase extends and incorporates the 
mutagenic primers, which results in a formation of nicked circular strands. After touchdown 
PCR, the methylated parental plasmid DNA is removed by digestion with DpnI. 
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Standard SDM mixture  
10x reaction buffer 5 µL 
50 - 100 ng plasmid 5 µL 
10 pmol/µL sense primer (5‘ - 3‘) 1.5 µL 
10 pmol/µL anti-sense primer (3‘ - 5‘) 1.5 µL 
dNTP-mix 1 µL 
QuikSolution reagent 3 µL 
QuikChange Lightning Enzyme 1 µL 
H2O 32 µL 
Final volume 50 µL 
 
PCR program for SDM 
Segment Cycles Temperature Time 
1 1 95 °C 2 min 
2 18 95 °C 20 sec 
60 °C 10 sec 
68 °C 30 sec/kb of plasmid 
length 
3 1 68 °C 5 min 
 
After PCR, 1 µL DpnI was added to the PCR-product and the mixture was incubated 1h at 37 
°C. Afterwards, 2 µL of the mixture were used for transformation of XL-10 Gold cells (2.2.1.1.). 
 
2.2.2.4 DNA Dephosphorylation 
In some cases, e.g. when only one enzyme was used for restriction of the plasmid, in order to 
prevent a re-ligation of a linearized plasmid, the restricted DNA was incubated with 3 µL 
Shrimp alkaline phosphatase (1 U/µL) for 1 h at 37 °C. 
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2.2.2.5 Amplification of DNA inserts using Polymerase Chain Reaction (PCR) 
All DNA was amplified with either the GoTaq system or in a nested touchdown PCR using the 
Expand High Fidelity PCR System.  
 
The PCR reaction using GoTaq: 
Master-mix GoTaq PCR  
5x colorless/green GoTaq reaction buffer 
with MgCl2 
10 µL 
dNTPs (10 mM) 1 µL 
10 pmol/µL sense primer (5‘ - 3‘) 5 µL 
10 pmol/µL anti-sense primer (3‘ - 5‘) 5 µL 
DNA 5 µL 
GoTaq DNA polymerase 0.25 µL 
H2O 23.75 µL 
Final volume 50 µL 
 
Two separate master mixes were prepared and mixed using the Expand High Fidelity PCR 
System: 
Master-mix PCRI  
5x reaction buffer with MgCl2 10 µL 
dNTPs (10 mM) 1 µL 
10 pmol/µL sense primer (5‘ - 3‘) 5 µL 
10 pmol/µL anti-sense primer (3‘ - 5‘) 5 µL 
cDNA 5 µL 
High Fidelity Polymerase 0.5 µL 
H2O 23.5 µL 
Final volume 50 µL 
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Master-mix PCRII  
5x reaction buffer with MgCl2 10 µL 
dNTPs (10 mM) 1 µL 
10 pmol/µL sense primer (5‘ - 3‘) 5 µL 
10 pmol/µL anti-sense primer (3‘ - 5‘) 5 µL 
DNA 2 µL 
High Fidelity Polymerase 0.5 µL 
H2O 26.5 µL 
Final volume 50 µL 
 
Touchdown PCR program for both reactions 
Segment Cycles Temperature Time 
1 1 95 °C 2 min 
2 2 95 °C 1 min 
66 - 57 °C 1 min 
3 1 72 °C 3 min 
4 15 95 °C 1 min 
57 °C 1 min 
72 °C 3 min 
5 1 72 °C 20 min 
6 1 4 °C    ∞ 
 
The size of amplified DNA fragments was assessed using ethidium bromide agarose gel 
electrophoresis. 
 
2.2.2.6 DNA restriction digestion 
Plasmids and PCR-products were restricted either with a single endonuclease or with a 
combination of two enzymes. The used enzymes were provided with a single buffer for all kinds 
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of restriction enzymes and all possessed a temperature optimum of 37 °C for reaction. The PCR 
products used for restriction were previously purified by extraction from the agarose gel. For 
preparative purposes up to 100 µL of restriction reaction was prepared and incubated for 30 min 
or in case of linearization overnight at 37 °C. The control digestion of successful cloning was 
carried out in 20 µL reaction for 10 min. 
 
Restriction of plasmids/PCR products 
10x green FD buffer 2 µL 
Plasmid DNA ( µg)/PCR 
Product ( µg) 
x µL 
FD Enzyme 1 µL 
H2O x µL 
Final volume 20 µL 
 
2.2.2.7 Agarose gel electrophoresis 
DNA fragments were separated in a horizontal 1-2% agarose gel containing 0.5 µg/mL of 
ethidium bromide. The electrophoresis was carried out in 1× TBE buffer at 120 V for 
approximately one hour. The visualization of the separated DNA fragments was performed using 
a UV-Bioimaging System (Syngene). 
 
2.2.2.8 DNA extraction from agarose gel 
Restricted plasmids or amplified DNA fragments were separated by agarose gel electrophoresis. 
The fragments of interest were cut out of the gel and purified with the QIAquick Gel Extraction 
Kit (Qiagen) according to the manufacturer’s protocol. The elution of purified fragments was 
performed in 30 µL of H2O. 
 
2.2.2.9 Cloning of PCR-products in intermediate plasmids 
In most cases the amplified DNA fragments were cloned in pCR4-Topo plasmid (Invitrogen) 
without additional gel purification, according to the manufacturer’s protocol. 
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pTopo cloning mixture  
PCR product (treated with Taq) 2 µL 
Salt solution 1 µL 
pCR4-Topo-vector 1 µL 
H2O 2 µL 
Final volume 6 µL 
 
The mixture was incubated for 45 min at room temperature and 2 µL were used for 
transformation of 25 µL supplied TOP 10 cells according to the standard protocol (2.2.1.1.). 
 
2.2.2.10   Phenol – chloroform purification 
For phenol–chloroform precipitation of the linearized plasmids two 100 µl restriction reactions 
were performed. After the digestion, the reactions were mixed by vortexing with 400 µl of 
phenol and centrifuged (16.000 xg, 10 min, 4 °C). The upper phase containing DNA was 
transferred to a fresh tube, mixed by vortexing with 250 µL of phenol and 250 µL of chloroform, 
and centrifuged (16.000 xg, 10 min, 4 °C). Again the upper phase containing DNA was 
transferred to a fresh tube and mixed with 500 µL of chloroform by vortexing and centrifuged 
(16.000 xg, 10 min, 4 °C). The DNA containing upper phase was mixed with 50 µL of 3 M 
sodium acetate (pH 7) and 500 µL of isopropanol. Then 1.5 µL of GlycoBlue were added and 
the mixture was incubated for 20 min at -20 °C. The tube was centrifuged (16.000 xg, 30 min, 
4°C), the supernatant was discarded and pellet was washed with 1 mL of 70 % ethanol (16.000 
xg, 10 min, 4 °C). The pellet was left to dry and afterwards suspended in 20 µL of nuclease-free 
H2O. 
 
2.2.2.11   Ligation of DNA fragments 
Purified, linearized plasmid and insert DNA were ligated using T4 DNA ligase. For the reaction 
a linearized plasmid/insert ratio of 1:3 - 1:6 was used, 1 µL of T4 ligase and 1 µL of 10x optimal 
ligation buffer (Rapid Ligation Kit, Roche) and the proper amount of ddH2O were added. The 
mixture was incubated 15-20 min at room temperature and used for transformation of competent 
E.coli cells. 
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2.2.2.12   Plasmid DNA purification using commercial kits 
One bacterial colony was picked up from the LB agar plate, using a sterile pipette tip and 
transferred into the flask with LB-medium containing selective antibiotic. The volume of 5 - 10 
mL of the culture was used for Mini, 100 mL for Midi, and 250 ml for Maxi preparations. After 
overnight incubation on the shaker at 37 °C the plasmid DNA was extracted using QIAprep Kits 
(Qiagen) according to manufacturer’s instructions. The DNA concentration was quantified by 
spectrophotometric OD260nm measurement as follows: 
 
Concentration [µg/mL] = OD260nm × dilution factor × 50  
 
Purified plasmid DNA was checked by control restriction digestion (section 4.1.4). 
 
2.2.2.13   DNA sequencing 
Sequencing was performed at the DNA-Sequencing Service of LGC Genomics. Non-standard 
primers designed for sequencing are listed in the Materials section (Tab. 3.5). 
 
2.2.2.14   In vitro transcription/production of HCV-plasmid-RNA 
After phenol/chloroform purification the linearized plasmid DNA was used as template for in 
vitro RNA transcription using the T7 Mega Script High Yield Transcription Kit (Ambion). 
 
Modified from manufacture‘s instructions  
Template DNA 10 µg 
ATP 2 µL 
CTP 2 µL 
GTP 2 µL 
UTP 2 µL 
10x reaction buffer 3 µL 
RNAse free water x µL 
T7 polymerase 2 µL 
Final volume 30 µL 
 
After incubation of the reaction for 4 h at 37 °C 1 µL of T7 polymerase was added and 
subsequently incubation for additional 2 h at 37 °C was performed. To remove the plasmid DNA 
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2 µL Turbo DNAse was added and the reaction was incubated for 30 min at 37 °C. After 
proteinase K treatment the transcribed HCV RNA was purified using the Mega Clear Kit 
(Ambion) according to manufacture‘s instructions. For protection of HCV RNA 1 µL of RNAse 
inhibitor was added per preparation. Concentration of RNA was determined by NanoDrop® 
from small aliquots and HCV RNA was stored at - 80 °C. 
 
2.2.2.15   HCVpp purification by ultracentrifugation  
The supernatant of transfected 293T cells containing the HCVpp was layered on 5 mL of 20 % 
(w/v) sucrose and centrifuged in rotor SW40 for 1.5 h at 40.000 rpm at 4 °C. The supernatant 
was discarded, the pellet was dissolved in 30 µL 2x Laemmli buffer and used for SDS-PAGE 
(2.3.4.2) followed by immonodetection (2.3.4.3). 
 
2.2.2.16   HCVcc precipitation 
HCVcc containing Huh7.5 cell culture supernatant was harvested and filtrated through a 45 µm 
membrane. The proper amount of a sterile 40 % (w/v) PEG 8000/PBS solution was added to the 
supernatant to final concentration of 8% PEG 8000, precipitation was performed over night at 4 
°C. 
 
2.2.2.17   HCVcc purification 
After PEG precipitation, the HCVcc containing cell culture supernatant was centrifuged for 1.5 h 
at 8000 xg and 4 °C in 50 mL Falcon tubes. Afterwards, supernatant was removed and the virus 
pellets were resuspended in 70 µL DMEM (10% FCS, 1% penicillin/streptomycin, 1% non-
essential amino acids, 1% HEPES) and used for serial dilutions (10-1 - 10-6) and TCID50. 
 
2.2.2.18   LightSNiP Assay 
Genomic DNA isolated from EDTA-blood of 92 AD78-infected patients was used for detection 
of single nucleotide polymorphisms of HCV cell receptor genes LDLR (low-density lipoprotein 
receptor), SCARB1 (scavenger receptor B1) and OCLN (occludin) by LightSNiP Assay (Tib-
molbiol). This test is based on melting curve analysis and is able to detect any mutation that is 
located within the sequence corresponding to the hybridization probe (TibMolbiol). In most 
cases these tests allow the differentiation between alleles (e.g. C/C, C/G or G/G): 
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Fig.  2.5 All reactions were performed according to manufacture‘s instructions. 
 
2.2.3 Cell culture 
2.2.3.1 Thawing and cryo-conservation of cells 
Cryo-tubes containing cells were taken out from the liquid nitrogen and thawed quickly in a 
warm water-bath. Cells were washed twice in 10 mL of the culture medium. Afterwards, cells 
were suspended in 10 mL of fresh medium, placed in 75 cm2 flask, and cultured at 37 °C in 
humidified atmosphere containing 5% CO2. 
For cryo-conservation, the cell suspension was centrifuged in 50 mL tubes (300× g, 5 min) and 
washed once with sterile PBS. The pellet was suspended in 1 mL of culture medium 
supplemented with 25% FCS and 10% DMSO. Cells were frozen slowly overnight in -80 °C and 
then transferred to a liquid nitrogen tank. 
 
2.2.3.2 Passaging of cells 
The medium was removed and cells were washed once with 15 mL of sterile PBS. Then 1.5 mL 
of Trypsin-EDTA was added to cover the bottom of the 75 cm2 flask. After 2 - 3 minutes when 
the cells started to detach from the bottom 8.5 mL of fresh medium was added. Cells were 
placed in fresh flasks in 20 mL of culture medium in the given concentration. 
 
2.2.3.3 Culture of Huh7.5 and Huh7.5.1 cells 
Adherent Huh7.5 or Huh7.5.1 cells were grown in monolayers in Dulbecco’s modified minimal 
essential high glucose medium (4,5 g/L) with L-glutamine supplemented with 10 % FBS, 1 % 
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penicillin/streptomycin, 1% HEPES and 1 % non-essential amino acids. Cells were passaged 
two times a week at a dilution of 1:3 or 1:5 depending on the confluence.  
 
2.2.3.4 Culture of HEK 293T cells 
Adherent HEK 293T cells were grown in monolayers in Dulbecco’s Modified Eagle Medium 1x 
(Gibco) containing 4.5 g/L glucose, L-glutamine, 25 mM HEPES, 10 % FCS, and 1 % 
penicillin/streptomycin. Cells were passaged 2 times a week at a dilution of 1:10 or 1:15 
depending on the confluence. 
 
2.2.3.5 Culture of human PBMCs/preparation of cryo-conserved PBMCs for peptide 
stimulation 
Human cryo-conserved PBMCs were gently thawed, suspended in 1 mL FCS and transferred to 
a 15 mL Falcon tube containing 20 µL of DNAse. Cells were washed 3x with 10 mL RPMI 
1640 (w/o supplements) and centrifuged for 7 min at 1800 rpm and room temperature. After the 
last centrifugation step cells were suspended in the appropriate amount (1 mL per stimulation) of 
RPMI (10 % FCS, 1 % penicillin/streptomycin, 1 % HEPES, IL-2 2.5 µL/mL, α-CD28 antibody 
1 µL/mL). For subsequent peptide stimulation of PBMCs 1 mL per well of cells was transferred 
to a 12 well plate and 1 µg/mL of the peptide of interest was added. Cells were incubated for ten 
days at 37 °C and 5 % CO2. Dependent on cell growth in culture cells were supplemented with 
additional 500 µL of RPMI (10 % FCS, 1 % penicillin/streptomycin, 1 % HEPES) containing 
2.5 µL of IL-2. 
 
2.2.3.6 Counting of viable cells using Trypan blue exclusion microscopy 
Trypan blue is a negatively charged dye that only interacts with the cell when the membrane is 
damaged. Therefore, all the cells, which exclude the dye, are viable. Aliquots of cell suspension 
were diluted with 0.4% Trypan blue stain and 10 µL of the diluted aliquot solution was 
transferred onto a Neubauer counting chamber. The viable cells were counted and the number of 
cells per mL was calculated as follows: 
 
Number of cells/mL = number of cells in the large square × dilution factor × 104 
 
2.2.3.7 Transfection of HEK 293T cells using CaCl2 method/production of HCVpp 
293T cells were harvested and seeded in a 10 cm2 dish at a final concentration of 2.5 x 106 cells 
in 8 mL medium (20-30 % confluence). The next day, the 293T cells were transfected with the 
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expression plasmid phCMV IRES-E1/E2 in combination with 2 retroviral plasmids encoding for 
HIV-Gag, Pol or Luc (pCMV delta R8.2; plasmid HPPT-EF1α- Luc) using the Calcium 
Phosphate Transfection Kit (Clontech). Briefly, 500 µL HBS 2x were put into a facs tube. Next, 
using an Eppendorf tube 1.5 ml, the mix was prepared as follows: 
 
pTopo cloning mixture  
H2O x µL 
phCMV-E1/E2 2.7 µg 
Plasmid encoding for Gag, Pol 8.1 µg 
Plasmid encoding for Luc 8.1 µg 
CaCl2 solution (added drop-wise) 62 µL 
Final volume 500 µL 
 
This mix was added drop-wise to the tube with 500 µL of g HBS 2x and incubated for 20 to 30 
min. at room temperature until the mixture becomes cloudy. After addition of this cloudy 
solution drop-wise to the cell culture, the dishes were incubated up to 16 h at 37 °C. The 
medium was changed and the cell culture was additionally incubated for 48 h at 37 °C. Finally 
the supernatant containing the generated HCVpp was harvested and centrifuged for 5 min at 
1200 rpm. The HCVpp preparation was aliquoted, frozen at -80 °C, and used for infectivity 
assay. 
 
2.2.3.8 P24 assay 
For quantification of HCVpp produced in 293T cells, cell culture supernatants were analyzed for 
p24 protein expression in the diagnostic department at University Hospital Essen. 
 
2.2.3.9 Infectivity assay 
Huh 7.5 cells were seeded in 96 well plates. For each plate, a master mix with 1.4 x 106 cells in 
20 mL medium was prepared. The next day, the medium was removed and HCVpp in 100 µL of 
Huh7.5 medium were added. After incubation for 4h at 37 °C, 200 µL of fresh pre-warmed 
Huh7.5 medium was added and plates were incubated for additional 72 h at 37 °C. For the 
infectivity evaluation, the medium was removed and 50 µL of Bright Glo lysis buffer (Promega) 
was added to each well and incubated for 2 h at - 20 °C. After thawing, 45 µL of prepared cell 
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lysates were transferred into a luminometer 96 well plate. Fifty µL of the Bright Glo Luciferase 
Assay buffer (Promega) were added and the luciferase-activity was immediately measured in the 
luminescence counter (Promega). All cell lysates were measured in triplicates and a mean value 
was calculated. 
 
2.2.3.10   Electroporation of Huh7.5 cells/production of HCVcc 
Huh7.5 cells were harvested from 75 cm2 flasks at a confluence of 40 - 70 % with 1.5 mL of 
Trypsin after washing with sterile PBS. All steps were performed at S3** level at room 
temperature. In Huh7.5 medium harvested cells were centrifuged for 5 min at 700 rpm in a 50 
mL Falcon tube. Supernatant was discarded and the cell pellet was suspended in 50 mL sterile 
PBS. A small aliquot was used for counting. Cells were centrifuged for 5 min at 700 rpm and the 
pellet was suspended in the needed volume of „Cytomix“ with freshly added 2 mM ATP and 5 
mM glutathione (1.5 x 107 cells/mL). For electroporation 400 µL of suspended cells (6 x 106 
cells/electroporation) were gently mixed by pipetting up and down 5 - 6 times with 50 µg of 
HCVcc RNA and immediately transferred into the electroporation cuvette. The cuvette was 
immediately transferred into the electroporation chamber and pulsed once as follows: 
 
975 µF; 270 V; expected time constant: ~ 24 ms 
 
Cells were directly transferred into 15 mL Huh7.5 medium in a 10 cm dish, the cuvette was 
rinsed several times. Cells were incubated at 37 °C and 5 % CO2 and next the medium was 
exchanged for 12.5 mL fresh Huh7.5 medium after washing once with PBS. After 72 h of 
incubation following electroporation supernatant was harvested and filtrated through a sterile 45-
µm filter. Subsequently, PEG-precipitation (2.2.2.17), HCV histochemistry (2.2.3.12) including 
TCID50 (2.2.3.11) were performed. 
 
2.2.3.11   Determination of the infectious HCVcc particle titer 
The titer of infectious HCVcc particles was determined using TCID50 (tissue culture infectious 
dose 50) assay. For that purpose, Huh7.5 cells were plated in a flat-bottom 96-well plate (6×103 
cells per well) and infected in every row (6 wells) with 100 µL of serial logarithmic dilutions 
(10-1 - 10-6) of the purified virus stock. After 72 h the infected cells were monitored. The ratio of 
NS5A-positive wells for every dilution was determined and the TCID50 per mL of the virus 
stock was calculated as follows: 
TCID50/mL = 101+d (S-0.5) × 10 
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Where: d = Log 10 of the dilution; S = the sum of infection ratios for every dilution  
 
2.2.3.12   HCV histochemistry (modified from Lindenbach et al., 2005) 
Huh7.5 cells were seeded at 6×103 per well on a poly-L-lysine coated flat-bottom 96-well plate 
(16 - 24h before infection) in a total volume of 200 µL DMEM per well. The serially diluted 
virus inoculum (10-1 - 10-6) was used for infection of 6 wells in a total infection volume of 100 
µL, respectively. Afterwards 100 µL Huh7.5 medium per well were added. After 72 h of 
incubation at 37 °C and 5 % CO2 cells were fixed with 50 µL of ice cold methanol (- 20 °C) and 
incubated at least for 15 min at - 20 °C (optional over night). Methanol was removed and cells 
washed once with PBS. By adding 50 µL of 0.5 % (v/v) Triton X-100 in PBS for 5 min at room 
temperature cells were permeabilized and afterwards washed once with PBS. Blocking of the 
plates was performed with 100 - 200 µL of blocking buffer for 1 h at room temperature on a 
shaker and afterwards washed once with PBS. The expression of NS5A by infected Huh7.5 cells 
was detected with the 9E10 primary antibody in a dilution of 1:2000 in PBS (50 µL/well). After 
incubation for 1 h at room temperature on a shaker plates were washed 3 x with PBS. Bound 
primary antibody was detected using anti-mouse HRP (Sigma, A4416) conjugated secondary 
antibody in a dilution of 1:200 and incubation for 1 h at room temperature on a shaker. Plates 
were washed 3 x with PBS and HRP activity was detected by adding DAB+ substrate (DAKO) 
and incubation for 30 min. Reaction was stopped by discarding the substrate and addition of 
H2O. Plates can be stored at 4 °C before microscopical analysis. 
 
2.2.4 Protein-biochemical and immunological methods 
2.2.4.1 Protein purification 
The medium of the Petri dishes (10 cm2) containing the transfected 293T cells was removed and 
dishes were immediately put on ice. In the next step, the cell dish was transferred onto ice and 5 
mL of ice cold PBS was added to each dish. The cells were scrapped and transferred into a 15 
mL Falcon tubes. A centrifugation step for 5 min at 1200 rpm at 4 °C was applied. The cell 
pellets were resuspended in 0.5 mL of non-denaturing lyses buffer and incubated on ice for 30 
min. The mixtures were clarified by centrifugation for 20 min at 4 °C at 12.000 rpm. Finally, the 
supernatant was transferred into a fresh tube and either stored at -20 °C or directly used for SDS-
PAGE. 
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2.2.4.2 SDS-PAGE 
Proteins were separated using the standard discontinuous SDS-PAGE (sodiumdodecylsulfate-
polyacrylamide-gel electrophoresis) in the Mini-Proteom chamber (BioRad). 
 
 stacking gel separation gel 12 % 
30 % Acrylamid solution (29:1) 0.75 mL 4.15 mL 
Tris-HCL (1 M, pH 6.8) 0.62 mL  
Tris-HCL (1.5 M, pH 8.8)  2.5 mL 
10 % SDS 0.05 mL 0.1 mL 
H2O 3.55 mL 3.25 mL 
 
For polymerization of the gels saturated APS solution (1:500) and TEMED (1:1000) were 
added. 
 
2.2.4.3 Immunoblot analysis (Western Blot) 
After the SDS-PAGE, the proteins were transferred from the gel to the nitrocellulose membrane. 
In this process membrane and gel were soaked in western-blot-transfer-buffer and placed 
between three layers of Whatman paper without air bubbles. The gel was turned towards the 
cathode and the membrane was turned towards the anode. Transfer took place for 15 minutes at 
7.5 V using the SemiDry-transfer chamber (Trans-Blot SD, BioRad). After the transfer, binding 
sites on the membrane were blocked with blocking buffer over night at 4 °C upon a gentle 
shaking. The Anti-HCV E2 antibody was diluted due to its optimal binding capacity in blocking 
buffer before incubation with the membrane for 1 h or, alternatively, overnight at 4 °C. 
Following 3 cycles of washing with T-PBS for 10 minutes, the membrane was incubated for 1 h 
with conjugate (anti-mouse or anti-goat peroxidase labeled IgG) diluted 1:1000 in the blocking 
buffer. Additional 3 steps of washing with PBS followed. Binding of the conjugate to anti-HCV 
antibodies on the membrane was detected on a radiographic film (BioMax Film, Kodak) by 
using ECL Western blotting detection reagents according to the manufacturer’s instruction. 
 
2.2.5 Flow cytometry 
Flow cytometry is a technology that simultaneously measures multiple physical characteristics 
of cells such as relative size, relative granularity and relative fluorescence intensity. The cells are 
transported in the fluid stream to the measuring cell where they are examined by the laser beam 
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one after another. Using monoclonal antibodies conjugated with a fluorescent dye, flow 
cytometry enables to identify a particular cell type within complex cell populations based on 
their individual antigenic markers. 
 
2.2.5.1 Staining of cells for flow cytometry analysis 
About 2x105 PBMCs per well and preparation were seeded in a round-bottom 96-well plate and 
centrifuged for 5 min at 1500 rpm, supernatant was discarded and the cell pellet resolved in 100 
µL RPMI 1640 (10 % FCS, 1% penicillin/streptomycin, 1 % HEPES). The relevant peptide 
(final amount 1 µg) was added to each well and cells were incubated for 5 h at 37 °C and 5 % 
CO2. Afterwards the plate was centrifuged for 5 min at 1500 rpm and supernatant was discarded. 
Cells were washed with 200 µL cold PBS/FCS (1% FCS in PBS) per well and centrifuged for 5 
min at 1500 rpm. Supernatant was discarded and cells stained for CD4 and CD8 molecules on 
their surface using anti-CD4-PE and anti-CD8-APC labeled antibodies (eBioscience) in a 
concentration of 1:1000, respectively, for 15 min at 4 °C. The plate was centrifuged for 5 min at 
1500 rpm and cells were washed with 200 µL cold PBS/FCS per well. Cells were fixed with 100 
µL IC Fixation Buffer (eBioscience) per well and incubated for 20 min at 4 °C. After 
centrifugation for 5 min at 1500 rpm supernatant was discarded and cells were washed with 200 
µL cold Perm Buffer (eBioscience). Intracellular IFN-γ staining was performed using IFN-γ- 
specific FITC-labeled antibody (eBioscience, 1:1000) in 100 µL Perm Buffer per reaction and 
incubation for 30 min at 4 °C. After centrifugation for 5 min at 1500 rpm cells were washed with 
200 µL cold Perm Buffer per well. After the last centrifugation step (5 min, 1500 rpm) cells 
were resuspended in 200 µL PBS per preparation and transferred to FACS tubes for subsequent 
FACS analysis. 
 
2.2.6 Phylogenetic analysis 
Phylogenetic analysis was performed according to the “Maximum-Likelihood” (ML) method 
using the phylip-3.69 software package. Up to 93 patient derived core-NS2 sequences were 
analyzed parallel with a set of reference sequences from the official HCV database 
http://hcv.lanl.gov/. Bootstrapping analysis assessed integrity of phylogenetic trees: 100 
randomized replicates of the dataset were analyzed. On the basis of the different newly grouped 
set of sequences it can be estimated to which extend a number of sequences from the same gene 
and the same species would influence the validation of the phylogenetic tree. 
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3 Results 
3.1 Generation of the HCV AD78 sequence database 
The first aim of the project was to establish a sequence database of the HCV strain AD78 that 
caused a single-source outbreak of hepatitis C in 1978 in East Germany. The AD78 cohort 
consisted of women infected by administration of an HCV contaminated anti-D globulin. This 
unique cohort provides the possibility to address many different questions dealing with multiple 
aspects of HCV research. During the study a bank of HCV AD78-related sequences 
corresponding to the genomic fragments core-NS2 and NS4-NS5A obtained from both the 
contaminated anti-D globulin batches and infected patients (n=93) was generated.  
 
3.1.1 Analysis of HCV AD78 core-NS2 sequences from the contaminated anti-D 
immunoglobulin 
To establish this database, the viral RNA was extracted from the contaminated anti-D 
immunoglobulin batches 8, 9, 12 and 15 and subjected to reverse transcription. Due to 
degeneration of the RNA molecules during the long-term storage of the globulins the core-NS2 
regions was amplified in four overlapping fragments. The PCR products were ligated into the 
TOPO-TA vector with sequencing of multiple clones. The phylogenetic analysis of the amplified 
sequences revealed that all HCV sequences derived from the contaminated globulin bathes were 
very closely related and were clearly separated from other HCV genotype 1b sequences 
available at the Los Alamos HCV database. Figure 3.1 illustrates these results and demonstrates 
that all sequences corresponding to the E2 genomic region (nt) from four batches of the anti-D 
globulin grouped together and that this cluster was separated from the bulk of other 1b 
sequences with a high statistical support. 
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Fig.  3.1 Unrooted neighbor-joining tree of the E2 nucleotide sequences, 
 obtained from HCV AD78-contaminated globulin batches 8, 9, 12, 15, and HCV 1b 
strains available from the Los Alamos HCV database. The bootstrapping value for 
AD78 sequences is indicated. 
  
3.1.1.1 Identification of three variants of the HCV AD78 strain present in the 
contaminated anti-D immunoglobulin 
 
Subsequent analysis of the heterogeneity of HCV clonal E2 sequences in the contaminated 
immunoglobulin (batches 8, 9, 12 and 15) revealed the presence of three closely related but 
genetically distinct variants of the AD78 strain in the infectious source (Fig.3.2). Of special note 
was the fact of unequal distribution of these three HCV AD78 variants (arbitrary designated as 
variants A, B, and C) in the different globulin batches. Figure 3.2 demonstrates that only 
globulin batch 12 contained sequences (labeled in blue) belonging to all three HCV A78 
variants. The other three batches contained sequences belonging to two (batch 8 sequences 
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labeled in blue) or only to one (batch 9 sequences labeled in green and batch 15 sequences 
labeled in light blue) variants of the HCV AD78 strain. Such heterogeneity might be a result of 
different concentration of the variants A, B and C in these batches and/or inability of the used 
PCR protocol to provide for amplification of these three variants with an equal sensitivity. In 
support of this hypothesis were the previous results of our laboratory 252. In this work the 
phylogenetic analysis of clonal NS3 sequences obtained from anti-D globulin batch 8 revealed 
the presence not of two, like in the current study, but of all three variants of the HCV AD78 
strain. To address this issue, amplification of the E2 region from the batch 8 was performed 
using variant C-specific primers. With this approach variant 3-specific sequences could be 
obtained from the globulin 8 (Fig.3.3 and Fig.3.4). These results have suggested that all batches 
of the anti-D globulin most probably contained all three variants of the HCV AD78 strain. 
 
Fig.  3.2 Rooted neighbor-joining tree of the E2 sequences, 
 obtained from anti-D globulin 8, 9, 12, and 15; separation of the AD78 strain into 
three closely related but genetically distinct variants (A, B, and C). The 
bootstrapping values are indicated. 
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Fig.  3.3 Rooted neighbor-joining tree of E2 nucleotide sequences, (without HVRI) obtained 
from the anti-D globulin batch 8. The bootstrapping values are indicated. 
 
98 
96 
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Fig.  3.4 Rooted neighbor-joining tree of E2 nucleotide sequences, 
 obtained from anti-D globulin batch 8, sequences for variant C amplified with 
variant-specific primers. The bootstrapping values are indicated. 
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3.1.1.2 Generation of the consensus sequences for the three variants of the HCV AD78 
strain 
The whole set of clonal core-NS2 sequences obtained from different batches of the contaminated 
anti-D globulin were used for construction of the consensus sequences for HCV AD78 variant 
A, B, and C, respectively. As expected upon phylogenetic analysis these three consensus 
sequences were clearly separated from the bulk of HCV 1b sequences from the Los Alamos 
HCV database (Fig.3.5)   
 
Fig.  3.5 Unrooted neighbor-joining tree of the three generated AD78, 
100 
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 consensus nucleotide sequences and randomly chosen HCV 1b nucleotide sequences 
from the Los Alamos HCV database. The bootstrapping value for HCV AD78 
consensus sequences A, B, and C is indicated.
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3.1.2 Analysis of HCV AD78 core-NS2 sequences from anti-D patients 
At the next step of the project the core-NS2 and NS4A-NS5A genomic regions were amplified 
from blood samples of 93 patients obtained 30 years after infection with the HCV AD78 strain 
through the administration of HCV contaminated anti-D immunoglobulin. The amplified DNA 
fragments were subjected to direct sequencing and subsequent phylogenetic analysis together 
with the consensus sequences of HCV AD78 variants A, B and C obtained from the 
contaminated globulin batches. All these sequences demonstrated close relatedness, formed a 
unique cluster and were clearly separated from the HCV 1b sequences collected in the Los 
Alamos HCV database (Fig.3.5), supporting a previous observation of our group that the HCV 
isolates, which caused the infection in the anti-D cohort, came from the same origin 252. 
Additional analysis of these sequences (Fig.3.6 and Fig.3.7) revealed that the cluster of anti-D 
sequences formed three different clades with a high bootstrapping support. This grouping 
corresponds to the three variants of the HCV AD78 strain identified in the contaminated 
globulin batches (Fig.3.2). Thus, the obtained data suggest that the infectious source 
(contaminated anti-D immunoglobulin) contained three closely related but genetically distinct 
variants of the same HCV AD78 virus strain and that all these virus variants were capable to 
initiate infection in the anti-D cohort. 
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Fig.  3.6 Unrooted neighbor-joining tree of 93 patient-derived HCV AD78 
 core-NS2 nucleotide sequences and the three consensus sequences for HCV AD78 
variants A, B and C. Bootstrapping values are indicated.  
 
 
Fig.  3.7 Unrooted neighbor-joining tree of 103 patient 
 derived HCV AD78 NS4-NS5 nucleotide sequences. Bootstrapping values are 
indicated. 
 
3.1.3 Analysis of E2 sequences of the HCV AD78 strain obtained from globulin donors 
Our data revealed heterogeneity of HCV AD78 sequences in the contaminated anti-D globulin 
batches. It was of interest to see if the three variants of the HCV AD78 strain were already 
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present in those donors, whose plasma samples were used for preparation of the anti-D globulin 
batches. Plasma samples from these 5 individuals, collected approximately 12 years later were 
available for analysis. Four of these samples were positive in RT-PCR and the obtained E2 
sequences were subjected to phylogenetic analysis together with E2 sequences amplified from 
anti-D patients collected 30 years after infection. Figure 3.8 indicates that the E2 sequences from 
3 of the secondary plasma donors grouped together with sequences belonging to variant C of the 
HCV AD78 strain. The sequence from the fourth donor localized in the clade formed by 
sequences belonging to variant B of this strain.  
 
Fig.  3.8 HCV AD78 variant attribution of the HCV E2 
 sequences amplified from donors, whose plasma was used for preparation of the 
anti-D globulin batches. Three sequences labeled in green and red grouped together 
with sequences belonging to the viral variant C. The fourth sequence labeled in blue 
was found in a cluster formed by sequences belonging to virus variant B. Sequences 
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from the anti-D patients and consensus sequences for HCV AD78 A, B and C 
variants are labeled in black. Bootstrapping values are indicated. 
3.1.4 Evolution of the HCV AD78 strain 
Generation of the HCV AD78 sequence database allowed initiating the analysis of HCV 
evolution in the anti-D cohort. The core-NS2 sequences obtained from contaminated globulin 
and anti-D patients were compared with the HCV subtype 1b general consensus sequence 
constructed from sequences available from the Los Alamos database. The consensus sequences 
for three variants of the HCV AD78 strain present in the contaminated globulin batches 8, 9, 12, 
and 15 were used as the anti-D-outbreak founder sequences. Table 3.1 lists the positions in the 
core-NS2 fragment, where at least one of the virus variant-specific consensus sequences from 
the infection source differed from the HCV 1b consensus sequence. Overall, 47 such positions 
were found – 2 in the core, 11 in the E1, 20 in the E2 (HVR1, HVR2 and HVR3 were excluded 
from this analysis), 3 in the P7, and 11 in the NS2 protein sequences. Upon normalization of 
these results by the size of these proteins the frequencies of sites of mutations were established. 
As expected, the lowest value (1%) was obtained for the core protein, which reflected a high 
conservation of this protein. For other proteins the frequencies varied within very narrow range, 
between 4.8 % for P7 to 5.7 % for E1, suggesting similar “rates of hot spot of mutation”. One 
should note, however, that for this analysis the HVRs 1, 2, and 3 were excluded from the E2 
sequences and real “rate of hot spot mutation” for this particular protein, therefore, is much 
higher.   
 
Table 3.1  Comparison of the HCV subtype 1b consensus sequence (aa) with HCV AD78 core-
NS2 amino acid sequences from the contaminated globulin (consensus sequences for HCV 
AD78 variants A, B and C) and anti-D patients. Bolt lines indicate the end/beginning of the next 
protein, starting with core till NS2. 
aa 
position 
Consensus 
1b 
AD78 variant A AD78 variant B AD78 variant C 
Source Patients 
(n=20) 
Source Patients 
(n=44) 
Source Patients 
(n=30) 
70 R Q R (16) R R (37) R R (23) 
91 M L L (21) L L (21) L L (26) 
202 H Q Q (17) H H (44) H H (29) 
216 A T T (20) T T (44) T T (30) 
233 N D D (12) D D (17) D D (19) 
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aa 
position 
Consensus 
1b 
AD78 variant A AD78 variant B AD78 variant C 
Source Patients 
(n=20) 
Source Patients 
(n=44) 
Source Patients 
(n=30) 
251 S S S (19) G G (31) G G (21) 
257 T T T (19) A A (32) A A (23) 
287 V V V (18) V V (37) I I (28) 
293 F F F (19) L F (30) L F (19) 
303 D E E (18) E E (32) E E (27) 
314 S T T (19) T T (43) T T (29) 
330 T A A (12) T T (43) T T (29) 
345 V V V (19) V V (41) M M (18) 
414 I V V (11) I I (33) V V (16) 
492 R Q Q (10) Q Q (23) Q R (18) 
501 Q Q Q (18) E E (40) E E (23) 
521 R R R (17) R R (41) H R (17) 
522 F F F (11) S F (29) S F (22) 
528 S S S (15) R R (24) S S (15) 
531 E A E (17) E E (39) E E (15) 
557 S T T (12) T A (22) T T (15) 
570 N K K (16) N N (39) K K (17) 
574 V L L (12) L L (27) L L (23) 
580 T I I (10) I I (25) I T (14) 
596 K R R (15) K K (42) K K (29) 
609 M I I (13) I I (35) I I (20) 
636 V V V (19) I I (41) I I (29) 
641 N S S (10) S S (20) S S (15) 
653 D G D (9) N N (29) N N (26) 
705 I V V (20) I V (25) I V (22) 
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aa 
position 
Consensus 
1b 
AD78 variant A AD78 variant B AD78 variant C 
Source Patients 
(n=20) 
Source Patients 
(n=44) 
Source Patients 
(n=30) 
708 A V V (20) V V (44) V V (29) 
709 V L L (18) L L (35) L L (26) 
719 V I I (20) I I (45) I I (30) 
759 V L L (20) L L (41) L L (29) 
790 F L L (17) L L (37) L L (14) 
792 G S S (17) G G (40) S S (24) 
824 V V I (10) I I (41) V V (14) 
827 A V V (13) V V (28) V V (24) 
834 H Y Y (18) Y Y (39) Y Y (27) 
841 R K K (20) K K (44) K K (30) 
861 I V V (19) I I (35) I I (23) 
864 V I V (19) V V (43) V V (30) 
885 I V V (19) I I (35) I I (23) 
891 I L L (20) L L (44) L L (30) 
906 I I I (19) I I (41) M M (29) 
938 F F F (12) L L (43) F F (28) 
1008 R K K (14) K K (29) K K (23) 
Amino acid positions as aligned to the hepatitis C virus genotype 1 reference (NC_004102) 
 
Most of the amino acid residues at the identified 47 sites were rather stable and were observed in 
sequences from most of the anti-D patients even after 30 years of infection. In 10 cases, 
however, reverse mutations toward the 1b consensus sequence were observed (positions 70, 293, 
492, 521, 522, 531, 580, 653, and 705). Interestingly, most of these reversions (7 of 10) occurred 
in the E2 protein. At one position (557) mutation away from the consensus 1b sequence (from 
threonine to alanine) was detected in 50 % of the sequences of the patients. In 3 cases, at 
positions 705 and 824, where the amino acid residues in 1b consensus and infectious source 
sequences were similar, forward mutations were identified the majority of sequences obtained 
Results 
 
 
74 
from patients. These data suggest that in the anti-D cohort reverse mutations toward the 
consensus 1b sequences at the “hot spot of mutations” sites were relatively rare.  
 
Evolution toward consensus sequence is considered as a relatively accurate assessment of a 
pressure toward optimal viral fitness. Therefore, at the next step, all mutations observed in the 
core-NS2 region in sequences obtained from all 93 anti-D patients were classified according to 
their direction – forward (away from the consensus sequences of AD78 variants A, B or C) or 
reverse (toward the 1b consensus sequence). The HVR1, HVR2 and HVR3 were excluded from 
this analysis. The obtained results are presented in figure 3.9 and complement those described 
above for the “hot spot of mutations” sites and indicate that in persistently infected anti-D 
patients virus genome evolution toward the general HCV 1b consensus sequence is relatively 
rare and observed in about 25-30 % of cases. 
 
Fig.  3.9 Frequencies of forward and reverse mutations, 
  accumulated during 30 years of infection in the core, E1, E2, p7, and NS2 sequences 
of HCV AD78 isolates from 93 patients. Total number of mutations is equal to 100 
%. 
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3.2 Generation of the new AD78/JFH-1 chimeric viruses  
The second aim was to generate chimeric viruses on the basis of the established consensus 
sequences (see section 3.1) for the three identified variants of the AD78 strain, that are capable 
of complete replication and infection in cell culture.  
 
The created core-NS2 consensus sequences of all three variants of the HCV AD78 strain were 
chemically synthesized and used for the generation of the AD78/JFH1 chimeric viruses 
(fig.3.10) (collaboration with Prof. R. Bartenschlager). The first experiments demonstrated 
viability of all three types of the chimeric viruses with a slightly better outcome for the HCVcc 
bearing the core-NS2 sequence from the consensus sequence of the variant A of the HCV AD78 
strain. 
 
Fig.  3.10 Scheme of the AD78/JFH1 chimeric virus 
 
At the next step the replication characteristic of this newly constructed AD78/JFH1 chimeric 
virus was assessed in four independent experiments. Results of the limited dilution assays 
presented in Figure 3.11 and 3.12 clearly demonstrate reproducibility of high levels of 
replication of the AD78/JFH1 virus comparable to that of the control H77/JFH1 chimeric virus. 
These results have indicated that the tested variant of the AD78/JFH1 chimeric viruses could be 
used in the subsequent experiments on the assessment of the influence of different mutations, 
including escape mutations, on HCVcc replication and infectivity. 
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Fig.  3.11 Determination of the infectivity of the newly AD78/JFH1, 
 chimeric virus in four independent experiments. The Huh7.5 cells were transfected 
with RNA transcribed from the AD78/JFH1 linearized plasmid. Supernatant 
collected 72 hours after transfection was used for infection of fresh Huh7.5 cells. 
After incubation for 3 days the infected cells were stained with monoclonal antibody 
directed against the NS5A protein. Virus titers were determined by TCID50 assay. 
The H77/JFH1 chimeric virus was used as a positive control. 
 
 
Fig.  3.12 Immunostaining of the infected Huh7.5 cells, 
 with monoclonal antibodies directed against the NS5A protein. (A) Uninfected 
control, (B) Huh7.5 cells infected with the AD78/JFH1 virus.  
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3.3 Study of the HLA class I-associated polymorphisms in sequences from 
the anti-D cohort and analysis of escape mutations 
The third aim of the current study was to assess the contribution of immune escape from the 
cellular immune response to evolution of the HCV E2 protein. A number of CD8 epitopes in 
HCV proteins has already been reported to the Immune Epitope Database 
(www.immuneepitope.org). One should note, however, that the available list of CD8 epitopes is 
far from being complete and novel epitopes are kept being identified during the last years 252. 
Thus, for the purpose of our project it would have been imperative to check for the presence of 
putative novel CD8 epitopes in the sequences from the AD78 cohort. Therefore, we have applied 
the bioinformatic approaches, developed by Prof. D. Hoffmann in collaboration with Prof. J. 
Timm, for analysis of the sequences from the generated HCV AD78 sequence database 252. With 
this approach a statistically significant association between expression of a particular HLA class 
I allele in patients and presence of amino acid substitutions at each site of the viral protein 
sequences in HCV isolates from patients was determined. An example for such an analysis for 
the HLA-B51 allele is presented in figure 3.13. Red dots located above the arbitrary cut-off 
value of p < 0.01 indicate 10 potential sites under HLA-B51 selective pressure. First, the 
sequences flanking the positions 147 and 153 in the core protein with the highest statistical 
significances were analyzed. Application of the binding prediction algorithms ANN and SMM 
(available at http://tools.immuneepitope.org) allowed identifying an HLA-B51-specific motif 
x[APG]xxxxxx[IV] around position 153 but not surrounding position 147. Sequences of anti-D 
patients, for whom data on HLA class I types were available (n=83), were aligned and stratified 
according to the expression of HLA-B51. A fragment of this alignment around position 153 is 
presented in figure 3.14. It is shown that 2 of 10 sequences from HLA-B51-positive patients bear 
the mutation H153Q. In contrast, such a substitution was absent in 73 sequences from HLA-
B51-negative subjects. A similar analysis of other potential sites (Fig. 3.13) did not reveal any 
evidences for HLA-B51 selective pressure. Overall, these data suggested the existence of a novel 
CD8 epitope restricted by HLA-B51 in the core protein sequences of the HCV AD78 strain. 
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Fig.  3.13 Identification of amino acid residues under selective pressure 
  in the presence of the HLA-B51 allele. The figure demonstrates the p-values for 
each amino acid position in the core-NS2 region. An arbitrary cut-off value of p < 
0.01 is marked with a dashed line. The positions above this threshold are marked in 
red and the big red asterisks indicate the sequence positions highlighted in fig. 3.14. 
 
 
Fig.  3.14 Polymorphism at positions 147 and 153 of the core sequences, 
 obtained from anti-D patients. Aligned sequences were stratified according to the 
expression of the HLA-B51 allele. Position of the predicted epitope is marked with a 
green frame. Two of 10 sequences from HLA-B51-positive (HLA-B51 +) patients 
showed a mutation at position 153, whereas the same substitution was absent in all 
73 sequences from HLA-B51 negative (HLA-B51 -) subjects. 
 
The same analysis was performed for other HLA class I alleles expressed by anti-D patients 
included into our study. Table 3.2 lists all 10 CD8+ T-cell epitopes with a statistical support for 
immune selection of the putative escape mutation identified with this approach. Three of them, 
in the core, E1 and NS2 proteins, were putative novel epitopes. 
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Table 3.2  CD8+ T cell epitopes/sequence regions with statistical evidence for selection by 
HLA-mediated immune pressure. 
Allele Position Protein Sequence p-value* CD8+ T cell response 
CD8+ T cell 
escape 
A03 43 - 51 core RLGVRATRK 0.014 + + 
A26 93 - 101 E1 EVRNVSGVY 0.0024 n.d. n.d. 
A2402 669 - 679 E2 LLSTTEWQI 0.008 + + 
A2404 679 - 687 E2 ILPCSFTTL 0.008 + n.d. 
B07 41 - 49 core GPRLGVRAT 0.0008 + + 
B51 142 - 160 core APLGGAARALAHGVRVLED** 0.0014 + n.t. 
B38 188 - 206 E1 PASAYEVRNVSGVYHVTND** 0.0005 n.d. n.t. 
B57 459 - 469 E2 RMASCRPIDKF 0.00003 n.d. n.d. 
B57 545 - 553 E2 NTRPPQGNW 0.0007 + + 
B08 958 - 972 NS2 TPLRDWAHAGLRDLA** 0.0002 n.d. n.t. 
* Fisher‘s exact test   **sequence regions containing potential novel epitopes identified in this 
study   n.d. - not detected   n.t. - not tested 
 
The statistical method used for the detection of epitopes and mutations that emerged under 
specific HLA class I selective pressure sometimes may provide false-positive results. Therefore, 
for identification “real” so far unknown epitopes inside viral proteins it can be used (in 
combination with the CD8 epitope binding prediction algorithm) only as a basic approach and 
needs an experimental verification. To provide an additional proof for the presence of novel 
epitopes or escape mutation in the already reported epitopes the peptides covering the regions of 
interest were designed. These peptides were used for the antigen-specific in vitro proliferation of 
PBMCs from the anti-HCV-positive, RNA-negative patient expressing relevant HLA class I 
allele. After 10 days of culture, PBMCs were re-stimulated with the same peptide, respectively. 
Subsequently, intracellular cytokine staining (ICS) for IFN-γ and FACS analysis were 
performed. Figure 3.15 exemplifies such an analysis for a putative novel HLA-B51 epitope 
identified in the core protein (Fig. 3.13 and Table 3.2). Stimulation of PBMCs with the peptide 
covering the region of interest led to increase in a number of cells (0.51%) producing IFN-γ. In 
control cell cultures stimulation with an HCV unrelated peptide did not increase the number of 
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IFN-γ producing cells (0.05 %) significantly. These results confirmed the existence of a novel 
HLA-B51 epitope within the peptide GAARALAHGVRVLED consisting of 15 residues, but the 
exact location of this epitope remained unknown 
 
 
Fig.  3.15 Intracellular cytokine staining (ICS) for a putative novel HLA-B51, 
 epitope inside the GAARALAHGVRVLED sequence region. PBMCs from an anti-
HCV positive RNA-negative patient expressing HLA-B51 were expanded with the 
peptide GAARALAHGVRVLED and subsequently re-stimulated with the same 
peptide. Production of IFN-γ was detected by ICS and subsequent FACS analysis. 
As a negative control, stimulation of CD8+ T cells with an irrelevant peptide was 
performed. 
 
As a next step, a fine mapping of this novel HLA-B51 epitope was performed with the help of a 
set of truncated versions of the GAARALAHGVRVLED peptide. Stimulation of HLA-B51-
specific PBMCs with these truncated peptides (Fig 3.16) revealed that only the peptide 
RALAHGVRV corresponding to the HLA-B51 binding motif x[APG]xxxxxx[IV] was 
recognized by CD8 T cells in the intracellular cytokine staining (ICS) assay, confirming that this 
peptide truly represents a novel HLA-B51- specific CD8 epitope. 
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Fig.  3.16 Fine mapping of a novel HLA-B51 epitope from the core protein. 
 PBMCs from an anti-HCV positive, RNA-negative patient expressing HLA-B51 
were expanded with 3 truncated variants of the peptide GAARALAHGVRVLED 
and subsequently re-stimulated with the same peptides. Production of IFN-γ was 
detected by ICS and subsequent FACS analysis. As a negative control, stimulation of 
CD8+ T cells with an unspecific peptide was performed. 
 
Two other putative new epitopes inside the E1 and NS2 proteins (table 3.2) were additionally 
tested by a functional assay in vitro. Peptides corresponding to these epitopes were not 
recognized by CD8+ T cells in an intracellular cytokine staining assay. Thus, these preliminary 
data performed with PBMC from only two subjects did not provide conformation of the 
existence of these two putative epitopes.  
 
Additional example of identification of the putative escape mutations in HCV AD78 core to NS2 
proteins driven by CD8+ T cell responses is presented in the next two figures. First, application 
of the statistical approach described above allowed for identification of several positions 
pointing to potential sites under HLA-B07-associated selection pressure (Fig. 3.17). One of these 
sites (position 43 in the core protein) was located in already described CD8 epitope 41-
GPRLGVRAT-49 in the core protein. Anti-D patient’s sequences corresponding to the region 
around this epitope were aligned (Fig. 3.18) and the frequency of amino acid exchanges was 
assessed. Eight of 17 sequences from HLA-B07-positive individuals contained substitutions 
R43K, R43T, and R43S in this epitope, whereas in the sequences from 66 HLA-B07-negative 
patients, mutation at this site (R43K) occurred only in one case. 
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Fig.  3.17 Identification of amino acid residues 
 under selective pressure in presence of the HLA-B07 allele. The figure demonstrates 
the p-values for each amino acid position in the core-NS2 region. An arbitrary cut-
off value of p < 0.01 is marked with a dashed line. The positions above this threshold 
are marked in red and the big red asterisk indicates the sequence position highlighted 
in fig. 3.18. 
 
 
 
 
 
 
 
 
 
Fig.  3.18 Polymorphism at position 43 of the core sequences 
 obtained from anti-D patients. Aligned sequences were stratified according to the 
expression of the HLA-B07 allele. Position of the known epitope is marked with a 
green frame. Eight of 17 sequences from HLA-B07-positive (HLA-B07 +) patients 
showed amino acid substitutions at position 43, whereas the residue exchange in this 
position occurred only in one of 66 sequences from HLA-B07-negative (HLA-B07 -) 
subjects. 
 
To get an additional proof for the presence of HLA-B07 driven escape mutations inside the 41-
GPRLGVRAT-49 epitope the peptides corresponding to the wild-type variant and the potential 
escape variants of the peptide were designed. The wild-type and mutant peptides were tested by 
an intracellular cytokine-staining assay. Figure 3.19 demonstrates the result of the FACS 
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analysis of peptide stimulated PBMCs. Appearance of the IFN-γ-producing cells was observed 
only in cultures stimulated with the original wild-type peptide GPRLGVRAT but not with the 
mutant peptides bearing the substitutions R43K, R43S, and R43T. These data confirm that the 
mutations occurring at position 43 inside the HLA-B07 epitope in the core protein are truly 
escape mutations.  
 
The same methodical approach was applied for analysis of other putative escape mutations 
identified in the current study (Table 3.2). Confirmation of the existence of HLA class I- 
associated escape mutations was obtained for 4 of 10 CD8 epitopes. 
 
 
Fig.  3.19 Identification of escape mutations in the HLA-B07 epitope 
  inside the core protein.  PBMCs from an anti-HCV-positive, RNA-negative patient 
expressing HLA-B07 were expanded with the wild-type peptide GPRLGVRAT or 
with the mutated peptides bearing the substitutions R43K, R43S, or R43T and 
subsequently re-stimulated with the same peptides. Production of IFN-γ was detected 
by ICS and subsequent FACS analysis. As a negative control, stimulation of CD8+ T 
cells with an irrelevant peptide was performed. 
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3.3.1 Influence of CD8+ T cell escape mutations on viral replication 
The detailed analysis of core-NS2 sequences obtained from the HCV AD78-contaminated 
globulin and anti-D patients led to the identification of CD8+ T cell escape mutations in this 
region (Table 3.2). Several recent studies, based on the application of the HCV subgenomic 
replicon system have shown that CD8+ T cell escape mutations inside the nonstructural HCV 
proteins can have severe fitness costs for the virus leading to a reduced replication capability 
252,256-259. We hypothesized that escape mutations identified in the structural genes of the HCV 
AD78 isolates in our study might also have a deleterious effect on the viral replication cycle. 
Generation of the AD78/JFH1 chimeric viruses with high replication potency in the framework 
of the current project made it possible to subject this hypothesis to experimental verification.   
 
At the first step, two identified HLA-B07- and HLA-B51- specific escape mutations inside the 
core region (R43K and H153Q) were introduced by site-directed mutagenesis into the 
AD78/JFH1 construct. Analysis of the infectivity of the resulting modified viruses in Huh7.5 
cell culture have shown that both escape mutations impaired virus replication, although to a 
different extent (Fig. 3.20). The escape mutation R43K led only to a relatively small reduction of 
the infectious titer of about one log. The mutation H153Q had a more pronounced effect on the 
viral infectivity, as the titer was reduced by approximately 2.5 logs (Fig.3.20). 
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Fig.  3.20 Influence of mutations in the core gene 
  on the infectivity of the AD78/JFH1 and H77/JFH1 viruses. Supernatant infectivity 
titers were determined by TCID50 assay. 
 
The core regions of HCV genotype 1a and genotype 1b genomes are highly homologous. As the 
AD78 strain belongs to the HCV genotype 1b we were interested to investigate the effect of the 
escape mutations found in the AD78 core region on the infectivity of HCV genotype 1a. For this 
purpose the escape mutations (R43K and H153Q) were introduced by site-directed mutagenesis 
into the chimeric H77/JFH1 virus, in which the structural HCV genes were derived from the 
HCV subtype 1a strain H77. As expected, the effect of the R43K substitution on viral infectivity 
was as mild (about one log) as that observed in the AD78/JFH1 system (Fig.3.20). In contrast, 
the H153Q mutation caused a dramatic loss of infectivity exceeding 6 logs. These data suggest 
that the impact of mutations (like H153Q), which cause relatively small impairment of the 
infectivity of one virus, might cause much stronger fitness cost for another virus belonging to 
different genotype or subtype. 
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At the next stage, using the AD78/JFH1 system we analyzed the biological effect of the escape 
mutations identified inside the HLA-A2402 (666-LLSTTEWQI-674) and the HLA-B57 (541-
NTRPPQGNW-549) epitopes, both located in the E2 protein of the HCV AD78 isolates (Table 
3.2). The mutations were introduced by site-directed mutagenesis into the chimeric construct and 
the resulting modified viruses were tested for infectivity by limited dilution assay in Huh7.5 cell 
cultures (Fig.3.21). No significant difference in the replication capacity of the virus bearing the 
HLA-A2402 I674V mutation was observed as compared to the parental wild-type AD78/JFH1 
virus. This unimpaired virus replication is in agreement with the observation that V at position 
674 is present in about 40% of the sequences of HCV type 1b strains included into the Los 
Alamos HCV sequence database.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.21 Influence of mutations in the E2 gene 
 on the infectivity of the AD78/JFH1 variant A virus. Supernatant infectivity titers 
were determined by TCID50 assay. 
Of special interest are the data on the identification of putative escape mutations at position 546 
in the HLA-B57 epitope 541-NTRPPLGNW-549 located in the E2 protein. Recently, conflicting 
data have been reported on association of this HLA-B57 epitope with spontaneous HCV 
clearance 197,201. It was suggested that these disparate results might be attributed to the 
polymorphism at position 546 201. Therefore, we decided to study the influence of the identified 
escape mutations at position 546 on viral fitness. The mutations were introduced by site-directed 
mutagenesis into the AD78/JFH1 construct and the infectivity of these modified viruses was 
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tested in Huh7 cell cultures (Fig.3.21). The virus bearing the mutation Q546R replicated as 
efficiently as the virus with the “wild-type” sequence, which contained Q at position 546. One 
should note that at position 546 the consensus HCV 1a sequence and consensus 1b sequence 
contain L and Q, correspondingly, and that many isolates belonging to genotype 1b have R at 
this positions. Therefore, it looks like the presence of Q or R at position 546 simply reflects a 
natural polymorphism and not the emergence of escape mutations. In contrast, introduction of 
the mutations Q546G and Q546A into the AD78/JFH1 construct led to a significant loss of 
replicative efficiency (drop by more than 2 logs) (Fig.3.21). These two substitutions are 
extremely rare in the subtype 1b sequences from the Los Alamos HCV sequence database. In 
sum, these results suggest that the amino acid substitutions Q546G and Q546A are real escape 
mutations that substantially impair viral replication and that the virus variants bearing these 
mutations are being eventually eliminated from the virus population in the majority of infected 
subjects. 
 
3.4 Influence of the specific antiviral cellular and humoral immune 
responses on envelope protein E2 evolution during a long-term virus 
persistence in anti-D patients 
There is a growing body of evidence for the fact that both cellular and humoral immune 
responses contribute to evolution of HCV proteins 26. At the same time, it is still not clear how 
big is the contribution of each type of the immune response to evolution of the envelope 
proteins, first of all, of the E2 protein. One possible approach to address this issue might be the 
assessment of selective pressures on HCV genome exerted by both the CD8+ T-cells and 
antiviral antibodies. 
 
The availability of the HCV AD78 sequence database generated in the current study provides an 
excellent opportunity to analyze some characteristics of the evolution of the E2 gene during 30 
years of viral persistence. First, we tried to assess how evident a contribution of the CD8+ T-
cells to evolution of the E2 gene is. The number of synonymous and nonsynonymous 
substitutions inside and outside of known CD8 epitopes was determined for each individual anti-
D patient according to his HLA class I genotype and a list of HLA type relevant CD8+ T cell 
epitopes. The aggregated data on the frequency of synonymous and nonsynonymous mutations 
inside and outside of all known CD8+ T-cell epitopes for all patients have not revealed 
significant difference between these parameters (Fig. 3.22), although, the statistical trend for a 
higher level of nonsynonymous mutations inside the CD8+ T cell epitopes was noted (p = 
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0.0684). These data suggest that the cellular responses promote the evolution of the E2 protein 
during the long-term viral persistence in the AD78 cohort; however, its influence probably is not 
profound. 
 
 
Fig.  3.22 Analysis of the frequency of synonymous and non-synonymous mutations 
 inside and outside of known CD8+ T-cell epitopes within the E2 gene. 
 
Next, we determined the extent to which a selective pressure of antiviral antibodies contributes 
to the rate of evolution of the E2 gene. To this end, the number of synonymous and 
nonsynonymous mutations inside and outside of previously described sites and regions 163,260-262 
involved into the reactivity with human monoclonal antibodies to E2 was calculated for all 
subjects from the anti-D cohort. The HVRI and HVRII fragments were excluded from this 
analysis. Data presented on figure 3.23 demonstrate that the difference in the frequency of 
mutations inside and outside of all known human monoclonal antibody-binding sites was 
statistically significant only for the nonsynonymous, but not for the synonymous substitutions. 
This suggests that the humoral immune response had a distinct impact on the viral envelope 
evolution in the AD78 cohort. 
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Fig.  3.23 Analysis of the frequency of synonymous and non-synonymous mutations 
 inside and outside of known human monoclonal antibody-binding sites within the E2 
gene. 
 
Overall, these data have shown that both cellular and humoral antiviral immune responses 
influence the HCV E2 protein evolution during a long-term viral persistence. Different 
frequencies of amino acid substitution inside and outside of B- and T-cell epitopes suggest that 
the specific humoral immune responses probably play a leading role in HCV E2 evolution in 
chronically infected patients. 
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3.5 Special structural feature of the HCV AD78 strain – presence of an 
additional amino acid track at the N-terminus of HVRI 
(Part of this work has been done in collaboration with Dr. M. Klein) 
 
Comparison of the clonal HCV AD78 sequences from different batches of the contaminated 
anti-D globulin performed in the current study revealed the presence of additional amino acid 
residues at the junction between E1 and E2 proteins: RGGG, GG and SALT in sequences of the 
HCV AD78 variants A, B and C, correspondingly (Fig. 3.24). Subsequent analysis of the HCV 
AD78 sequence database generated in the current study has shown that this peculiar structural 
feature (presence of an additional amino acid track) was observed in the majority (83 %) of the 
sequences from anti-D patients. At that, the length of this insert varied from 1 to 4 residues. 
Twelve percent of sequences contained one, 22 % - two, 36 % - three, and 30 % - four additional 
residues. 
 
Fig.  3.24 Additional amino acid residues at the E1/E2 junction 
 in the sequences of variants A, B and C of the HCV AD78 strain present in 
contaminated anti-D globulin. 
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Table 3.3 Changes of the additional amino acid track at the E1/E2 junction in sequences of anti-
D patients obtained 30 years after infection. 
Sequences from: 
HCV AD78 strain 
Variant A Variant B Variant C 
Infectious 
source (anti-D 
globulin) 
RGGG --GG SALT 
Anti-D patients 
RGGA SRPR AAPS 
HTYD -VYA TASS 
-VQA -ASA VTST 
-SAK -RFS -TAL 
--SG --LA -AVS 
--EM --RG -RAS 
--NT ---GE --YS 
---Q ---S --SP 
---T ---E --VR 
---- ---- ---- 
 
3.5.1 Frequency of additional amino acid stretches in different HCV genotypes and 
characteristics of the inserted residues 
Next, we searched for the presence of additional amino acid stretches in the sequences of 
different HCV genotypes and subtypes (Table 3.4). Overall, the frequency of such inserts in 
HCV sequences is low. At that, significant variations of the frequencies of those inserts in 
sequences belonging to different genotypes were observed. The additional amino acid residues 
occurred much more often in genotype 1b and 2 sequences than in sequences belonging to 
genotypes 1a and 3 (p < 0.0001). Of note is the fact of variable number of additional codons in 
sequences of different HCV types. Thus, for example, among HCV 1b strains we observed from 
1 to 4 additional codons, while among genotype 2 strains this number varied from 2 to 5 codons. 
It is tempting to speculate that some sequences belonging to genotype 1b and 2 may have some 
specific structural features, which facilitate the emergence of these inserts at this particular 
position of the polyprotein. Application of several programs, which allow predicting the RNA 
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folding, did not, however, reveal any differences between sequences with and without additional 
codons at the E1/E2 gene junction. 
 
Table 3.4 Frequency of additional codons at the 5‘ end of HVR1 sequences of HCV isolates of 
different types from the Los Alamos hepatitis C sequence database (related sequences are 
excluded). 
 gt 1a 
(n=7146) 
gt 1b 
(n=3489) 
gt 2 
(n=496) 
gt 3 
(n=1711) 
gt 4 
(n=137) 
gt 5 
(n=64) 
gt 6 
(n=96) 
1 codon 0 20 0 0 1 0 0 
2 codons 4 7 2 0 0 0 0 
3 codons 0 2 2 0 0 0 0 
4 codons 2 1 3 1 0 0 0 
5 codons 1 0 3 0 0 0 0 
At least 
one 
additiona
l codon 
7 (0.1 %) 30 (0.9 %) 5 (1 %) 1 (0.06 %) 1 (0.7 %) 0 0 
 
Next, the analysis of the physico-chemical characteristics of the additional amino acid residues 
was performed. Its results have shown a restricted amino acid usage with predominance of small 
and flexible residues, especially at the very N-terminus, as well as the low frequency of Pro and 
large hydrophobic residues. Another important feature was the predominance of neutral and 
hydrophobic residues; three residues – Cys, Trp, and Asp were absent. Thus, the additional 
amino acid set was characterized by low frequencies or absence of residues known to restrict 
changes in a polyprotein conformation. Overall, these results suggested a selection for particular 
residues in the additional amino acid tracks located at the E1/E2 junction. 
 
Presence of the additional amino acid residues at the E1/E2 junction raise the question to what 
protein these residues remain fused after the proteolytic processing of the viral polyprotein. 
Comparative analysis of the E1 C-terminal sequences (including the signal peptide segment) of 
HCV strains from the Los Alamos HCV database demonstrated absence of any special amino 
acid substitutions in this area in strains bearing the additional amino acid residues. Such a 
conservation of the E1 sequences provides for a proper processing signal and strongly suggests 
the invariable processing pattern. Thus, despite the absence of direct experimental proof, one 
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might reasonably assume that the additional amino acid residues observed at the E1/E2 junction 
just behind the cleavage site upon a processing became a part of the N-terminal sequence of the 
E2 protein. 
 
The identified restriction of physico-chemical characteristics of residues forming the additional 
amino acid stretch at the N-terminus of HVRI suggest that these stretches should have a 
particular conformation and, most probably, are involved in interaction with the rest of HVRI 
and/or the E1/E2 heterodimer. This might lead in turn to changes of infectivity of HCV particles. 
To address this issue, two experimental approaches for measuring the HCV infectivity – the 
HCVpp and HCVcc systems –were used.  
 
3.5.2 Impact of amino acid insertions on infectivity 
First, a set of HCV AD78 E1/E2 expressing plasmids was generated to assess the influence of 
the additional amino acids at the N-terminus of the HVRI on infectivity of HCVpp. Two 
phCMV-IRES plasmids expressing the E1/E2 gene sequences corresponding to the consensus 
sequences of HCV AD78 variants A and B were used as a backbone for all subsequent 
manipulations. Four codons (encoding RGGG) in case of the virus variant A and two codons 
(encoding GG) for variant B at the 5’-end of HVRI present in these E1/E2 sequences were 
deleted or modified by replacing them with several natural or artificial amino acid stretches 
(Table 3.5). All these modified plasmids were used for transfection of HEK 293T cells. The 
levels of expression of the HCV envelope proteins were tested by Western blot (Figure 3.25). 
The supernatants of these cultures were harvested and virus pseudo-particle concentration was 
determined by p24-test (quantification of Gag). HCVpp-containing supernatants were 
normalized according to p24 concentrations. The prepared sets of HCVpps were used for 
infectivity assays in Huh7.5.1 cells following a standard protocol.  
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Table 3.5 Modifications of the additional amino acid track at the N-terminus of HVRI in the 
E1/E2 consensus sequences of HCV AD78 variants A and B used for preparation of the 
expressing plasmids.  
Additional amino acid 
stretch in HCV AD78 
variant A sequence 
Source 
Additional amino acid 
stretch in HCV AD78 
variant B sequence 
Source 
RGGG (RG3) 
HCV AD78 variant A 
(wt) --GG 
HCV AD78 variant B 
(wt) 
w/o additional stretch 
(Δ 4 aa) 
HCV AD78 variant A 
without 4 aa 
w/o additional stretch 
(Δ 2 aa)---- 
HCV AD78 variant B 
without 2 aa 
-HGG sequence from anti-D 
patient T98 
RGGG (RG3) HCV AD78 variant A 
(wt) 
SASP sequence from anti-D 
patient B98 
---S sequence from anti-D 
patient T90 
-ASA sequence from anti-D 
patient H98 
-TSW sequence from anti-D 
patient T94 
-MSV sequence from anti-D 
patient H98 
-MSG sequence from anti-D 
patient T98 
SGQL consensus HCV type 1b 
sequence 
-ASA sequence from anti-D 
patient T06 
TSSHV consensus HCV type 2 
sequence 
DNDN absent or rare amino 
acids 
DNDN absent or rare amino 
acids 
- - 
RG6 artificial stretch - - 
RG9 artificial stretch - - 
(w/o = “without”) 
 
 
 
 
 
 
Fig.  3.25 Immunodetection of HCV AD78 E2 protein 
 expressed in 293T cells. Cell lysates of the 293T cells transfected with the 
expression vector phCMV-IRES encoding the E1/E2 sequences of different HCV 
AD78 variants were subjected to SDS-PAGE. Consensus HCV AD78 variant B 
sequence was used as a backbone. The description of all modifications is listed in 
table 3.5. Proteins were transferred to the nitrocellulose membrane and immuno-
stained with mouse monoclonal antibody to HCV 1b E2 (α-E2 CET-3 mAb).  
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Comparison of the infectivity of the generated set of pseudo-particles bearing either the original 
E2 consensus sequence of the HCV AD78 variant A or its modifications listed in table 3.5 have 
demonstrated that the presence (or absence) of an additional amino acid track in all cases but one 
(insertion of the DNDN) did not result in a significant change of infectivity (Fig. 3.26). A 
significant drop of infectivity was observed only after insertion of the DNDN sequence that 
consisted of residues, which are never (D) or exceptionally rarely (N) present in the context of 
additional amino acid stretches in HCV sequences. These data suggest that the presence of 
additional amino acid residues at the N-terminus of HVRI probably has no significant influence 
on virus infectivity. Principally, the same results were obtained upon assessment of infectivity of 
HCVpps bearing either the original E2 consensus sequence of the HCV AD78 variant B or its 
modifications listed in table 3.5. Despite more distinct variations of the infectivity levels in most 
of these cases no significant reduction of infectivity was registered (Fig. 3.26). The only 
exception was observed with particles bearing the E2 sequence with a deletion of the additional 
amino acid residues. Sequence analysis revealed the presence of proline at the first position of 
HVR1 in the consensus sequence of HCV AD78 variant B. Site-directed mutagenesis of the 
residue at this position was performed. Substitution of the Pro to Thr led to a partial restoration 
of the infectivity of pseudo-particles with a deleted additional amino acid residues (Fig. 3.28). 
The Western blot analysis has shown a reduced level of the E2 in HCVpp bearing E2 sequence 
without additional amino acid residues (Fig. 3.25 and 3.27) and the appearance of the E2 
polypeptide band in HCVpp preparation bearing the HVRI with the exchange of Pro by Thr 
(Fig. 3.27). These results suggest that presence of Pro at first position of the HVRI probably 
causes a disruption of the polyprotein processing between E1 and E2 proteins. This interesting 
observation warrants a further more detailed investigation. 
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Fig.  3.26 HCVpp infectivity assay with pseudo-particles 
 bearing wild type and modified E2 sequences. RGGG - construct bearing the wild 
type sequence of the HCV AD78 variant A. w/o add. aa - the same construct but 
with deleted RGGG insert (all other constructs see table 3.5). (w/o = “without”) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.27 HCVpp infectivity assay with pseudo-particles 
 bearing wild type and modified E2 sequences. Wt var B-GG – construct bearing the 
wild type sequence of the HCV AD78 variant B prior to HVRI. w/o add. aa - the 
same construct but with deleted GG insert. RGGG - construct bearing the wild type 
sequence of the HCV AD78 variant B with the RGGG insert of AD78 variant B 
prior to HVRI. (all other constructs see table 3.5). (w/o = “without”) 
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Fig.  3.28 HCVpp infectivity assay with pseudo-particles  
 bearing wild type and modified E2 sequences. Wt var B-GGP – construct bearing the 
wild type sequence of the HCV AD78 variant B with the GG insert and P at first 
position of the HVRI.  Δ-P – the same construct but with deleted GG insert. Δ-T - 
construct bearing the wild type sequence of the HCV AD78 variant B with the GG 
insert and T instead of P at first position of the HVRI. No Env – negative control. 
 
 
 
 
 
 
Fig.  3.29 Immunodetection of HCV AD78 E2 proteins expressed in 293T cells.  
 Cell lysates of the 293T cells transfected with the expression vector phCMV-IRES 
encoding the E1/E2 sequences of different HCV AD78 variants were subjected to 
SDS-PAGE. Consensus HCVAD78 variant B sequence was used as a backbone. Pro 
at first position of the HVRI was substituted by Thr using a site-directed 
mutagenesis. The proteins were transferred to the nitrocellulose membrane and 
immunostained with mouse monoclonal antibodies to HCV 1b E2 protein (α-E2 
CET-3 mAb).  
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As has been documented above, the frequencies of additional amino acid stretches at the N-
terminus of HVRI are much higher (p < 0.0001) in sequences from HCV 1b strains that from 1a 
strains (Table 3.4). Thus, it looks like the absence of such additional stretches is an intrinsic 
characteristic of HCV 1a viruses. The HCV AD78 strain belongs to subtype 1b and the genome 
of the majority of its isolates contains these inserts. It was of interest to see if introduction of the 
additional amino acid residues into the genome of 1a virus would influence its replication 
potentials. We decided to apply the HCVcc system to measure the influence of the additional 
amino acid tracks at the N-terminus of HCV AD78 isolates on virus infectivity. Three constructs 
were used for this investigation: AD78/JFH1 based on the consensus HCV AD78 variant A 
sequence containing the additional amino acid stretch RGGG at the N-terminus of HVRI; 
H77/JFH1 wild type (wt), and modified H77/JFH1 bearing the additional RGGG track (Fig. 
3.27).  Introduction of the RGGG sequence at the N-terminus of the E2 protein encoded by H77 
sequence caused a dramatic impairment of infectivity of H77/JFH1 virus while the AD78/JFH1 
chimeric virus bearing the same additional RGGG track was highly infectious. These results 
complement data on a low frequency of additional amino acid residues at the E1/E2 junction in 
HCV type 1a strains (Table 3.4) and suggest that for some unclear reasons most of the genotype 
1a viruses (including the H77 strain) are unable to tolerate the extension of length of HVRI at its 
N-terminus. Further intensive studies are necessary to clarify this intriguing issue. 
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Fig.  3.30 Influence of mutations in the E2 gene 
 on the infectivity of the AD78/JFH1 and H77/JFH1 viruses. Supernatant infectivity 
titers determined by TCID50 assay. 
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3.6 Genetic heterogeneity of HCV cell entry receptors in the AD78 cohort 
Analysis of clonal core-NS2 sequences of the HCV AD78 in globulin batches 8, 9, 12, and 15 
revealed the presence of three closely related but distinct virus variants of the same strain 
(section 3.1). In the phylogenetic analysis of viral sequences from the anti-D patients a relatively 
even distribution of these three virus variants was observed. Important to note, that according to 
the data of our group (Viazov, unpublished, 252) none of the patients was infected with more than 
one virus variant, suggesting a selection mechanism for a particular virus variant in each patient. 
To prove the hypothesis that heterogeneity of HCV cell receptors might have influence on HCV 
variant selection, single-nucleotide polymorphisms (SNPs) in major HCV cell receptor genes 
from anti-D patients were investigated. Selection of the SNPs for analysis was performed on the 
basis of data kept at dbSNP-polymorphism repository (http://www.ncbi.nlm.nih.gov/SNP/ and 
ExPASy Molecular Biology Server http://www.expasy.ch/). We searched for SNPs that caused non-
synonymous substitutions and, which occurred with relatively high or unknown frequencies. 
According to these criteria, seven SNPs, 2 for the LDLR (low-density lipoprotein receptor) gene, 
3 for the SCARB1 (scavenger receptor B1) gene, and 2 for the OCLN (occludin) gene were 
chosen for subsequent analysis (Table 3.6). Two of the receptors molecules, CD81 and Claudin-
1 were found to be quite conserved. 
 
Genomic DNA isolated from EDTA-blood of AD78-infected patients was used for detection of 
SNP by LightSNiP Assay (Tib-molbiol). This test is based on melting curve analysis and is able 
to detect any mutation that is located within the sequence corresponding to the hybridization 
probe. 
 
Table 3.6 Summary of selected SNPs for analysis. 
Receptor gene Polymorphism 
LDLR 2x SNPs (rs11669576, 
rs45508991) 
SCARB1 3x SNPs (rs5890, rs74830677, 
rs77554031) 
CD81 conserved 
OCLN 2x SNPs (rs2666626, 
rs79095497) 
claudin-1 conserved 
 
The melting curve analysis for the LDLR SNP rs45508991 showed that 32 investigated 
sequences bear the C/C allele and none contained the C/T or T/T allele. The results for the 
LDLR SNP rs116697576 demonstrated that 61 of 64 DNA sequences were positive for the G/G 
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allele and 3 sequences positive for the G/A allele. Thus, both investigated LDLR SNPs were 
predominantly present in a monoallelic manner. These results suggest that these SNPs did not 
have influence on the HCV AD78 variant selection in the AD78 cohort (Fig.3.31). 
 
 
Fig.  3.31 The LightSNiP assay for the LDLR gene.  
 All investigated sequences (n= 32) were found to be homozygous (C/C allele) with 
respect to the SNP rs45508991. The SNP rs11669576 was present as G/G allele in 
61 of 64 investigated DNA sequences; three individuals were positive for the G/A 
allele. On the graph representative results for 32 DNA samples are shown. 
 
The melting curve analysis for the SCARB1 SNPs rs77554031, rs74830677 and rs5890 showed 
that all 32 investigated DNA sequences were homozygous for the tested polymorphisms. Thus 
these SNPs seemed not to have any influence on the HCV AD78 variant selection in the anti-D 
cohort (Fig.3.32). 
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Fig.  3.32 The LightSNiP assay for the SCARB1 gene.  
 All investigated sequences (n= 32) were found to be homozygous (T/T allele, C/C 
allele, and G/G allele, respectively) with respect to the SNPs rs77554031, 
rs74830677, and rs5890. 
 
The melting curve analysis for the OCLN SNP rs790995497 showed that 32 investigated 
sequences did bear the T/T allele and none contained the T/C or C/C alleles suggesting that these 
SNPs seemed also not to have influence on the HCV AD78 variant selection in the AD78 cohort 
(fig3.33). The LightSNiP assay results for the OCLN SNP rs2666626 showed that DNA 
sequences from 28 of 92 anti-D subjects were positive for the G/G allele; all other 64 sequences 
were positive for the G/C allele (Fig.3.33). Subsequently, the frequencies of the G/G and G/C 
alleles of the OCLN SNP rs2666626 in patients infected with different HCV AD78 variants was 
checked (Fig.3.34). Upon this analysis no association between distribution of the OCLN SNP 
rs2666626 and presence of a particular HCV AD78 strain variant was found.  
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Fig.  3.33 The LightSNiP assay for the OCLN gene.  
 All investigated sequences (n= 32) were found to be homozygous (C/C allele) with 
respect to the SNP rs79095497. The SNP rs2666626 was present as G/G allele in 28 
of 92 investigated DNA sequences; 64 individuals were positive for the G/C allele. 
On the graph representative results for 32 DNA samples are shown.  
 
Fig.  3.34 Frequencies of the G/G and G/C alleles, 
 of the OCLN SNP rs2666626 in patients infected with different HCV AD78 
variants. 
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In summary, no evident correlation between HCV cell receptor polymorphism and presence of a 
particular virus variant was noted. Heterogeneity of the receptors LDLR, SCARB1 and OCLN 
seems not to play an important role in the mechanism of virus selection at the stage of viral entry 
in case of natural HCV infection with multiple virus variants. 
  
Discussion 
 
 
105 
4 Discussion 
The accumulating data show that the specific anti-viral immune response of the host is a major 
factor of HCV genome evolution 26,155,159,254. According to the concept of immune escape 
mechanism, the quasispecies nature of HCV population in the infected host provides a basis for 
a selection of resistant variants of the virus under both humoral and cellular immune pressure 
and, as a result, cells bearing the viral genomes with the escape mutations are not eliminated, 
and HCV persistence is established. There is a growing number of publications, which 
demonstrate adaptation of HCV to humoral or cellular immune pressure by selection of escape 
mutations in targeted B- and CD8 T-cell epitopes in individual patients 26,169,245-247.  At the same 
time, it is not completely clear if the frequencies and characteristics of the immune escape 
observed in individual patients are reproducible at the population level. Several studies 
addressed this issue and have shown a reproducible selection pressure in a number of CD8 T-cell 
epitope in subjects with the same HLA class I type 26,250,252. One should note that all of these 
studies dealt predominantly with the analysis of the epitopes located in nonstructural proteins of 
HCV and the degree, to which both cellular and humoral immune selection pressure contribute 
to evolution of the envelope proteins, remains unclear.  One of the aims of the current project 
was to find answer to this important question and to get an insight into the role of humoral and 
cellular immune responses in evolution of the envelope protein E2 of HCV. Studies in this field, 
however, usually are hampered due to the fact that investigators have to deal with patients 
infected with different HCV strains and no information on the ancestral virus sequences is 
available. The essential feature of the project was the use of a special group of patients – women 
infected with the same HCV strain (AD78) by administration of the contaminated anti-D 
globulin in a single-source outbreak. This unique cohort of patients infected with the same virus 
strain allowed for minimization of factors, including route of transmission, size of inoculum, 
duration of infection, age and sex of infected individuals, playing a significant role in evolution 
of the virus during the chronic infection.  
 
The first step of the current work was the generation of the HCV AD78 sequence database. The 
core-NS2 and NS4A-NS5a genome regions of the HCV AD78 strain from contaminated 
globulin batches and anti-D patients serum samples collected 30 years post infection were 
amplified and the genetic heterogeneity of HCV AD78 isolates was investigated.  Previous data 
from our group (252; Viazov et al, unpublished), based on the study of the heterogeneity of the 
NS3 and NS5B genes, demonstrated that the HCV AD78 outbreak was in fact caused not by one 
but by three closely related but slightly different variants of the AD78 virus strain. The results 
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obtained in the current study upon an analysis of the created HCV AD78 sequence database 
confirmed the previous data from our group and suggested the presence of these three virus 
variants in each of the anti-D globulin batches. Interestingly, the genetic heterogeneity of the 
infectious source of the HCV AD78 outbreak distinguishes it from the well-known HCV 
outbreak, which occurred in 1978 in Ireland and was caused by a contaminated anti-D globulin 
that contained only one variant of the founder virus 248. 
 
Of special interest is the question, in which individual(s) the three variants of the HCV AD78 
have arisen from the original variant of this strain. The available history of the anti-D outbreak, 
which took place in East Germany in 1978, indicates that the “source” of the original virus 
(index HCV AD78-infected donor) provided blood for preparation of the erythrocytes 
concentrate. This concentrate was used for immunization of 5 individuals (secondary plasma 
donors). Three to five weeks later the plasma of these 5 subjects was mixed in different 
proportions and used for preparation of eight immunoglobulin lots (batches 8 to 15). Two of 
these donors later on developed jaundice. A phylogenetic analysis of the E2 sequences from 4 of 
these secondary plasma donors, collected approximately 12 years after blood donation, was 
performed in the current study. It revealed that one subject has been chronically infected with 
the HCV AD78 variant B, while three others were infected with the variant C of this virus strain. 
The presence of HCV AD78 variants in different secondary plasma donors and persistence of 
the same virus variant in three of them allow us to rebut a hypothesis that splitting of the original 
HCV AD78 strain into the three lineages occurred during the acute infection of these secondary 
plasma donors 252. It is likely that the separation of the original HCV AD78 strain into the three 
variants might have taken place during the chronic infection of the index donor.  An alternative 
explanation could be the existence of more than one index donors already infected by closely 
related variants of the same virus strain. These subjects probably were the remunerated donors 
engaged by the same blood collection center and were persistently infected with the HCV AD78 
strain. Cross-contamination of these donors in the blood center and circulation of the same virus 
among them for years could have eventually led to a separation of the HCV AD78 strain into the 
three variants. In our opinion, to clarify the issue and to find the answers to most of the questions 
will be possible only if the samples from the index HCV AD78-infected donor and/or other 
donors from the same blood center become available for a detailed analysis. 
 
Establishment in the framework of the current study of the HCV AD78 sequence database 
provided a basis for a series of experiments. First of all, availability of the clonal core-NS2 
sequences from different batches of anti-D globulin led to the generation of the consensus 
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founder sequences for HCV AD78 variants A, B and C. These three consensus sequences were 
used in collaboration with the group of Prof. R. Bartenschlager for the development of the HCV 
AD78/JFH1 chimeric viruses.  These new constructs were viable and capable of initiating 
relatively high levels of virus replication in Huh7.5 cells. Availability of such robust cell culture 
system represents a significant step in the extension of the currently available JFH1-based 
systems of genotype 1. Especially promising these new chimeric viruses are for the studies based 
on the materials from the HCV-AD78 outbreak. In particular, this system is essential for 
elucidation of the biological significance of the mutations occurring in the viral genome during 
both acute and persistent phases of infection. 
 
Analysis of the generated HCV AD78 sequence database allowed identifying 47 positions in the 
core-NS2 fragment, where at least one of the virus variant-specific consensus sequences from 
the infection source is differed from the HCV 1b consensus sequence. Remarkably, most of 
these substitutions were very stable and have not been changed in most of the anti-D patients 
even after 30 years of viral persistence. Interestingly, about 40% of these stable substitutions 
were located inside the CD8 epitopes, suggesting that these mutations did not compromise 
substantially a viral fitness in a spectrum of hosts. An alternative explanation might be a 
presence in most of these sequences of additional compensatory mutations, which reconstitute, 
at least to some extent, the replicative capacity of the mutated viruses. Availability of the AD78-
based HCVcc system makes it possible now to subject this intriguing topic to experimental 
verification.  
  
It is important to note that only 10 of 47 substitutions (21%) reverted toward HCV 1b consensus 
sequence over 30 years.  These data are complemented by our analysis of all mutations that were 
observed in the sequences from all the patients from the anti-D cohort, where selection of the 
general consensus 1b residue occurred only in a minority of cases. In sum, the obtained data 
indicate that in persistently infected anti-D patients evolution of the virus genome toward the 
HCV 1b consensus sequence is relatively rare and observed in about 25-30% cases. 
 
For a further analysis of the generated HCV AD78 sequence database a statistical sequence 
analysis algorithm was applied 252. This approach is directed at the detection of a statistically 
significant association between expression of a particular HLA class I allele and presence of 
amino acid substitution at each site of viral protein sequence and allowed for identification of 
sites under selective CD8 T-cell immune pressure at a population level.  Implementation of this 
type of analysis led to identification of HLA class I specific polymorphisms inside 7 already 
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described CD8 epitopes in the core, E1, E2, and NS2 proteins. Introduction of two identified 
HLA-B07 and HLA-B51-specific escape mutations into the genome of the HCVcc constructs 
have impaired virus replication. However, for the HLA-B51-specific mutation (H153Q) a 
reduction of the infectious titers depended very much on the origin of the sequence included into 
the HCVcc genome. This mutation caused relatively mild impairment of the infectivity of the 
AD78/JFH1 virus, while in the H77/JFH1 virus it led to a dramatic loss of infectivity exceeding 
6 logs. These data indicate that the impact of the escape mutations on viral fitness might to a 
significant extent depend on the sequence context. Moreover, this conclusion might apply not 
only to viruses belonging to different subtypes of the same genotype but, probably, even to 
different strains of the same subtype. From this point of view, availability of the AD78/JFH1 
system, as well as of materials from anti-D outbreak, provide us with a unique possibility to 
assess the biological significance of different mutations in the context of a homologous genomic 
sequence. 
 
Of special interest are the results of the testing of mutations in the HLA-B57 epitope in the E2 
protein. A protective character of HLA-B57 allele has been described for a group of patients 
predominantly infected with HCV subtype 1a 201.  At the same time this allele was not protective 
in the Irish anti-D outbreak caused by 1b virus 197 and seems not to be protective in German anti-
D cohort. The consensus 1a sequence contains L at position 546, while the Irish 1b strain 
contained R546. The HCV AD78 strain as well as the consensus 1b sequence has Q546. We 
have introduced the putative escape mutations in the HLA-B57 epitope (Q546G and Q546A), as 
well as substitution Q546R into the AD78/JFH1 construct and measured the infectivity of the 
resulting mutant viruses. Substitutions Q546G and Q546A caused a drastic drop of infectivity 
(more than 2 logs) and, probably, represent real escape mutations. In contrast, both viruses 
bearing Q or R at position 546 replicated equally well. It is likely that the Q/R polymorphism is 
a general characteristic of the HCV 1b strains and has nothing to do with the escape mechanism. 
Most probably, the disparate results on the protective value of the HLA-B57 E2 epitope are due 
to the fact that the Q/R variants of this epitope are not recognized by HLA-B57-restricted 
responses.  These data highlight the fact that minor differences between sequences of HCV 
subtypes (and probably even between some strains of the same subtype) might have important 
consequences for the CD8 T-cell responses and ability to contain HCV infection. 
 
Important aspect of immunological research of HCV infection deals with identification of novel 
CD8 epitopes. In most of the publications on epitope mapping the series of overlapping peptides 
derived from the HCV 1a sequences were used. This approach is rather cumbersome and not 
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always provides the unambiguous results. We decided to use an alternative approach, which 
revealed its value in the recent study of nonstructural NS3 and NS5 proteins 252. At the first step, 
a statistical approach for detection of the HLA class I-associated polymorphisms in sequences 
from the anti-D cohort was used. The identified polymorphic sites were further evaluated with 
the epitope prediction programs for the relevant HLA allele, and the peptides covering the region 
under interest were investigated by antigen-specific expansion of PBMC obtained from HLA-
relevant patients and subsequent intracellular cytokine staining after re-stimulation with the 
same peptide. This combined approach allowed us to get a confirmation of existence and to 
perform a fine mapping of one novel epitope in the core protein. We were not able to get an 
experimental conformation by a functional assay for other two potential epitope candidates 
despite the fact that high statistical support for a strong HLA-associated selective pressure was 
obtained. One should note, however, that for confirmation by a functional assay the samples 
from intravenous drug users were used. It is unclear to which genotype/subtype and exact 
sequence these subjects had been exposed to. Therefore, one should consider the negative results 
of the functional assay with a caution. This issue warrants farther, more detailed investigation. 
 
The data demonstrating the HLA-associated polymorphism in the core, E1, E2, and NS2 protein 
sequences from anti-D patients provided evidence that positive selection pressure by CD8 T-
cells plays a role in evolution of these proteins, including E2. In order to assess a contribution of 
both the cellular and humoral immune responses to evolution of the E2 protein gene in 
sequences from anti-D cohort the frequencies of synonymous and nonsynonymous substitutions 
inside and outside of known B- and CD8 T-cell epitopes was determined. As expected, no 
differences were observed in the frequency of synonymous mutations both inside and outside of 
these B- and T-cell epitopes. In contrast, a statistical trend was noted for a higher mutation rate 
inside CD8 epitopes compared to regions outside, indicating that selection pressure by CD8 T-
cells evidently has some influence on evolution of the E2 protein in this group of patients. One 
should note, however, that novel CD8 epitopes are being continuously identified (225,252; current 
study) and that the real rate of evolution at nonsynonymous sites inside the CD8 epitopes might 
be somewhat higher. Importantly, the elevated mutation frequency of nonsynonymous mutations 
within the binding sites and regions described for human monoclonal anti-HCV antibodies rather 
than outside of these areas was registered and the observed difference was highly significant. In 
sum, these data suggest that both specific antiviral humoral and CD8 T-cell immune responses 
contribute to the E2 evolution during the long-term HCV persistence. At that, the humoral 
response probably plays a leading role, while the contribution of the CD8 T-cell response seems 
to be less profound.    
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Development of the HCV AD78 database also allowed us to identify a peculiar structural feature 
of the viral genome – the presence of additional codons at the E1/E2 gene junction. Previously, 
insertions at this position have been reported both for the AD78 strain 263 and other HCV isolates 
177,264,265. Our data have extended these original findings and indicated that such insertions may 
not only be found in sequences of a small number of HCV isolates but, in fact, may be present in 
the majority of isolates of a particular HCV strain. The functional meaning of naturally 
occurring amino acid stretches at the N-terminus of HVRI has not been investigated yet. Using 
the HCVpp system we have shown that presence of these stretches in the context of AD78 
sequence had no significant influence on infectivity of pseudovirus particles. Application of a 
more sensitive and reproducible HCVcc system has demonstrated that the chimeric AD78/JFH1 
viruses bearing the sequences of 3 variants of the HCV AD78 strain, which contained the 
insertions RGGG, GG, or SALT were highly infectious. These results mean that the RNA 
molecules with additional codons at the E1/E2 junction, which are found in HCV particles from 
patients’ sera, are not artifacts or by-products of RNA replication, but genomes of viable virions. 
Overall, these data indicate that at least some of the HCV strains can tolerate the insertion of 
additional amino acid stretches at the N-terminus of HVRI and that these insertions have no 
evident influences on replicative potentials of these viruses.  It is important to note, however, 
that the presence of additional amino acid residues at the E1/E2 junction   may have important 
impact on structure and function of envelope proteins of HCV. In the current study the physico-
chemical characteristics of the stretches of amino acid residues encoded by additional codons 
were analyzed.  The predominance of neutral and hydrophobic residues in most of the observed 
positions of additional amino acid tracks suggested that these stretches might be oriented toward 
the hydrophobic E2 protein core. A high prevalence of small and flexible residues in these 
stretches, especially at the very N-terminus, might facilitate the maintaining of the varied 
conformational states of the HVR I. Absence of Trp and Cys, as well as the very low frequency 
of Pro evidence for this hypothesis. Finally, an enlargement of the HVR1 could affect some 
functional characteristics of the E2 protein, including its antigenic properties and ability to 
recognize and bind to HCV cell receptors. 
 
Another interesting question concerns the limit of the length of the fragment that can be inserted 
at the E1/E2 junction. Our data have demonstrated preservation of the infectivity of HCVpp after 
insertion of the artificial RG30 track into the E1/E2 sequence derived from the AD78 strain 
(Viazov et al., in preparation). Recently, a report on the insertion of the flag tag at the E1/E2 
junction of the chimeric J6/JFH1 virus was presented 213. The modified virus with insertion of 13 
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additional amino acid residues was fully viable and retained its physico-chemical properties. 
Thus, at least for the genotypes 1b and 2 the presence of relatively long amino acid tracks at the 
N-terminus of E2 does not lead to a significant impairment of replicative potentials of the virus. 
In contrast to these findings, however, are the data indicating that the maximal length of 
insertions at this site in naturally occurring HCV isolates is five residues. These data suggest an 
existence in vivo of a selective mechanism that restricts the size of insertions at the N-terminus 
of the E2 protein.  
 
The results of a longitudinal study performed by our group have shown that for most HCV 
AD78 isolates from the anti-D cohort no conservation of the length or composition of the 
additional amino acid stretches at the N-terminus of the E2 was observed (Viazov et al., in 
preparation). These findings may be explained by the naturally occurring quasispecies dynamics 
of HCV populations and raise the question on specificity of the mechanism of generation of such 
insertions. Considering very low frequency of amino acid insertions at this site in genotype 1a 
and 3 sequences, one might suggest that genomic sequences of some HCV isolates possess 
certain structural features, which facilitate the appearance of these insertions. Casino et al. 
suggested a mechanism of generation of extra codons at the extreme 5’-end of the E2 gene 264. 
They have observed an imperfect direct repeat in the clonal sequence of one HVRI variant and 
suggested that a COOH-terminal region of the HVRI was duplicated and replaced the NH2-
terminal region resulting in appearance of one extra amino acid residue. Our analysis of the E2 
sequences retrieved from the Los Alamos HCV database as well as from the generated AD78 
dataset did not reveal the presence of any repeat in any sequence. Moreover, our attempts to 
identify any differences in secondary structure of viral RNA molecules of HCV isolates with and 
without extra codon insertions by application of several RNA folding prediction programs were 
unsuccessful. Thus, the insertion of additional amino acid stretches at the N-terminus of the E2 
protein represents a very interesting structural feature of many HCV isolates and functional 
significance of such inserts warrant further, more detailed studies. 
 
One of the interesting observations in the current study as well as of our previous investigations 
(Viazov et al, unpublished; 252) is that none of the anti-D patients harbored more than one variant 
of the HCV AD78 despite the fact that the inoculum, the anti-D globulin batches contained all 
three variants of the virus. These data suggest the existence of mechanism(s) that restrict either 
the coinfection of hepatocytes with two or several virus variants or superinfection or both. In 
favor of this postulate are the data on a very low frequency of mixed infection in HCV infected 
subjects, including multiple exposed individuals 266. Recently, a phenomenon of HCV 
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superinfection exclusion by already infected Huh7 hepatoma cells due to interference at the level 
of HCV RNA translation and/or replication has been described 267,268. Such a restriction may 
also function at other stages of the HCV replicative cycle, including the entry step. Thus, the 
Huh7 cells infected with one HCV strain demonstrate downregulation of expression of two key 
factors for HCV entry – claudine-1 and occludin 269. Our data showing an absence of mixed 
infection of anti-D patients with two or three variants of HCV AD78 allowed us to propose 
another explanation of the restriction phenomenon. It is possible that one or several of the HCV 
cell receptors in cells from anti-D patients are heterogeneous and that polymorphism of these 
receptors might have influence on HCV variants selection in case of an inoculum containing a 
mixture of viruses. The anti-D cohort represented a unique group to verify this hypothesis. A 
single-nucleotide polymorphism (SNP) in major HCV cell receptors LDLR, SCARB1, and 
OCLN genes from anti-D patients was analyzed. No evident correlation between HCV cell 
receptor polymorphism and presence of a particular virus variant was found. These data indicate 
that heterogeneity of the tested major HCV cell receptors is very low and has no influence on the 
selection of virus variants at the stage of virus entry. 
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5 Summary 
The specific anti-viral immune response of the host is considered as one of the major factors of 
HCV genome evolution. Adaptation of the virus to both cellular and humoral immune pressures 
by selection of the escape mutations in the targeted B- and T- epitopes is the basic mechanism of 
the evolution. Many details of HCV adaptation to selective forces, both in individual patients 
and, especially at the population level, are not completely clear. The current study address 
several aspects of this issue and its major aim was to get an insight into the evolution of the 
HCV genome at a population level and, in particular, into the contribution of humoral and 
cellular immune responses to evolution of the HCV envelope protein E2.  
 
Many investigations of HCV evolution were hampered by the absence of information on the 
viral ancestral genomic sequence. The essential characteristic of the current project was the use 
of a special group of patients – women infected with the same HCV AD78 strain via 
contaminated anti-D globulin in a single-source outbreak. This allowed performing the accurate 
analysis of viral evolution at a population level using the HCV AD78 sequences present in the 
anti-D globulin as the index founder sequences. 
 
At the first stage of the project a sequence database (core-P7 and NS4-NS5 genomic fragments) 
for multiple isolates of the HCV AD78 strain obtained from 93 anti-D patients persistently 
infected for 30 years and from contaminated immunoglobulin was generated.  
 
Availability of this database allowed to analyze in detail the heterogeneity of the infectious 
source of the anti-D outbreak and to establish a potential time point of separation of the original 
HCV AD78 strain into the three closely related variants. This led to the establishment of the 
consensus sequences for 3 variants of the HCV AD78 strain. These sequences have been used in 
collaboration with the group of R.Bartenschlager for generation of the novel chimeric 
AD78/JFH1 viruses, which were capable to replicate in Huh7.5 hepatoma cells to high levels. 
Availability of such robust cell culture system represents an important step in the extension of 
the currently available JFH1-based systems of genotype 1. Especially promising are these new 
chimeric viruses for studies based on the materials from the HCV AD78 outbreak. In particular, 
this system is essential for elucidation of the biological significance of the mutations occurring 
in viral genome during both acute and persistent phases of infection. 
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Analysis of the heterogeneity of HCV AD78 sequences from anti-D patients has demonstrated a 
number of mutations both inside and outside of the CD8 T-cell epitopes and antiviral antibody 
binding sites and regions. Both reverse (toward the consensus 1b sequence) and forward (away 
from the infecting inoculum sequence) mutations were present with a predominance of the latter. 
A large number of mutations inside the CD8 epitopes were remarkably stable over 30 years of 
persistence. A least some of them were real escape mutations that, most probably, were 
preserved due to appearance of the compensatory mutations. The analysis of the frequency of 
mutations inside and outside of known and putative B- and T-cell epitopes within the E2 protein 
from AD78 isolates has shown higher rates of nonsynonymous amino acid substitutions inside 
the B-cell epitopes and, to a lesser extent inside the CD8 epitopes, than outside of these epitopes, 
suggesting that both humoral and CD8 T-cell immune responses contribute to the E2 evolution 
during the long-term HCV persistence. At that, the humoral response probably plays a leading 
role, while the contribution of the CD8 T-cell response seems to be less profound.    
 
Application of a statistical approach allowed for identification of three putative novel CD8 T-
cell epitopes in the core, E2 and NS2 proteins; one of them was confirmed by a functional assay 
in vitro. In several known CD8 epitopes an association between expression of different HLA 
class I alleles and presence of particular polymorphic sites was reproducibly found, suggesting 
immune pressure at the population level. Introduction of several escape mutations, identified in 
the core and E2 proteins, into the genome of the HCVcc constructs has impaired virus 
replication confirming that these were truly escape mutations. For the HLA-B51-specific 
mutation H153Q a reduction of the infectious titers depended very much on the origin of the 
sequence included into the HCVcc genome. This mutation caused relatively mild impairment of 
the infectivity of the AD78/JFH1 virus, while in the H77/JFH1 virus it led to a dramatic loss of 
infectivity exceeding 6 logs. These data indicate that the impact of the escape mutations on viral 
fitness to a significant extent might depend on the sequence context.  
 
Generation of the HCV AD78 sequence database also allowed identifying a peculiar structural 
feature of some HCV strains - presence of additional 1 to 5 amino acid residues at the N-
terminus of the E2 protein. Most of the AD78 isolates demonstrate the presence of such inserts. 
Both the HCVcc system and the HCVpp–based approach were used for analysis of the influence 
of the additional amino acid tracks on virus infectivity and replication. Presence of such inserts 
in the HCVpp bearing the AD78E1/E2 sequence or in the AD78/JFH1 virus has not significantly 
changed the infectivity of virus particles. In contrast, the insertion of the same additional 
stretches into the H77/JFH1 virus, which bears the structural genes of the H77 subtype 1a strain, 
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caused a complete abolishment of infectivity. Analysis of the composition of these additional 
amino acid stretches has shown a high prevalence of small and flexible residues, which might 
facilitate the maintenance of the varied conformational states of the HVRI. That, in turn, could 
affect some functional characteristics of the E2 protein, including its antigenic properties and 
ability to recognize and bind to HCV cell receptors. 
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6 Zusammenfassung 
Die spezifische, antivirale Immunantwort des Wirtes stellt einen der Hauptfaktoren für die 
Evolution des HCV Genoms dar. Die Anpassung des Virus an den zellulären und humoralen 
Selektionsdruck erfolgt über die positive Selektion von „escape“-Mutationen in B- und T-Zell 
Epitopen und stellt den Basismechanismus der HCV Evolution dar. Viele Aspekte, die 
besonders auf Populationsebene zur Adaption von HCV an selektive Einflüsse führen, sind noch 
nicht ausreichend untersucht. Die vorliegende Studie befaßt sich mit einigen dieser Aspekte, 
wobei das Hauptziel in der Untersuchung der Evolution des HCV Genomes auf 
Populationsebene lag. Besonders der Beitrag der humoralen und zellulären Immunantwort zur 
Evolution des HCV Hüllproteins E2 wurde untersucht. 
 
Viele Ansätze, die sich bisher mit der Evolution von HCV beschäftigten, waren relativ 
eingeschränkt, da keine Informationen über die ursprüngliche Sequenz des Inokulums vorlagen. 
Eine große Besonderheit der vorliegenden Studie ist die Untersuchung einer einzigartigen 
Patientengruppe - Frauen, die mit demselben HCV AD78 Stamm durch Verabreichung eines 
HCV kontaminierten anti-D Immunglobulins in einem „single-source“-Ausbruch infiziert 
wurden. Durch den Zugang zu verschiedenen Materialien dieser Kohorte war eine detaillierte 
Analyse der viralen Evolution auf Populationsebene möglich, wobei die AD78 Sequenzen im 
kontaminierten Immunglobulin als Indexsequenzen dienten.  
  
Im ersten Schritt des Projektes wurde eine Sequenzdatenbank (core-NS2 und NS4-NS5 
Genomregion) für multiple Isolate des HCV AD78 Stammes von 93 Patienten erstellt, welche 
persistierend über einen Zeitraum von 30 Jahren mit HCV AD78 infiziert waren, sowie von 
Sequenzen aus dem kontaminierten Immunglobulin. 
 
Mit Hilfe der erstellten Sequenzdatenbank konnte die Heterogenität der Infektionsquelle des 
anti-D Ausbruchs detailiert analysiert werden und ein potenzieller Zeitpunkt der Separation des 
original AD78 Stammes in die drei eng verwandten Varianten konnte festgelegt werden. 
Außerdem konnten die Konsensusequenzen für alle drei AD78 Varianten erstellt werden, auf 
deren Grundlage in Kollaboration mit Prof. R. Bartenschlager die neuen AD78/JFH1 
Viruschimären generiert wurden. Diese neuen chimären Konstrukte waren in der Lage, 
erfolgreich in Huh7.5 Zellen zu replizieren. Die Verfügbarkeit dieses neuen und robusten 
Zellkultursystems stellt einen bedeutenden Schritt für die Erweiterung der bisher kreierten JFH1-
basierten Genotyp 1b Systeme dar. Besonders geeignet sind diese neuen Viruschimären für 
Summary 
 
 
117 
Studien, die sich mit Proben des HCV AD78 Ausbruchs befassen. Dieses neue System stellt ein 
essentielles Hilfsmittel für die Aufklärung der biologischen Signifikanz von Mutationen, die im 
viralen Genom während der akuten und persistierenden Phase der Infektion auftreten, dar. 
 
In der Analyse der Heterogenität von HCV AD78 Sequenzen aus anti-D Patienten wurden 
verschiedene Mutationen innerhalb und außerhalb von CD8 T-Zell-Epitopen und 
Bindungsstellen für neutralisierende Antikörper identifiziert. Mutationen weg von der 
Inokulumsequenz (forward mutations) wurden dabei häufiger detektiert als Mutationen in 
Richtung der allgemeinen 1b Konsensusequenz (reverse mutations). Eine große Anzahl von 
Mutationen innerhalb von CD8 T-Zell-Epitopen zeigte sich als bemerkenswert stabil in einem 
Zeitraum von 30 Jahren Persistenz. Einige von diesen Mutationen waren echte „escape“ 
Mutationen und wurden durch das Auftreten von kompensatorischen Mutationen in der 
Population fixiert. Die Analyse der Frequenz von Mutationen innerhalb und außerhalb von 
bekannten und putativen B- und T-Zell-Epitopen im E2 Protein aus AD78 Isolaten zeigte eine 
höhere Rate nonsynonymer Aminosäuresubstitutionen innerhalb von B-Zell-Epitopen und 
weniger ausgeprägte nonsynonyme Mutationen innerhalb von CD8 T-Zell-Epitopen. Diese 
Mutationen konnten vermehrt innerhalb bekannter Epitope beobachtet werden, als außerhalb 
dieser Epitope, was daraufhin deutet, dass sowohl die humorale als auch die zelluläre 
Immunantwort zur Evolution des E2 Hüllproteins in der langzeit-persistierenden HCV Infektion 
beitragen. Desweiteren scheint die humorale Immunantwort eine leitende Rolle in der Evolution 
des HCV E2 Proteins einzunehmen, wogegen die CD8 T-Zell Antwort einen geringeren Einfluß 
auf die Entwicklung des HCV E2 Proteins zu haben scheint. 
    
Die Anwendung eines statistischen Ansatzes ermöglichte die Identifikation von drei putativen 
neuen CD8 T-Zell-Epitopen im core, E2 und NS2 Protein. Eines der potenziellen neuen Epitope 
konnte mittels funktionellem in vitro Zellkultur-Assay verifiziert werden. Innerhalb einiger 
bekannter CD8 T-Zell-Epitope konnte reproduzierbar eine Assoziation zwischen Expression 
eines bestimmten HLA Klasse 1 Allels und dem Auftreten bestimmter Polymorphismen an 
definierten Positionen hergestellt werden, was auf eine Immunselektion auf Populationsebene 
hindeutet. Die Einführung verschiedener „escape“ Mutationen, die in der core- und E2-Region 
identifiziert wurden, in das Genom von HCVcc Konstrukten führte zu einer Beeinträchtigung 
der Virusreplikation und Infektion. Diese Daten bestätigen, dass die beobachteten 
Polymorphismen tatsächlich „escape“ Mutationen waren. Im Falle der HLA-B51 spezifischen 
Mutation H153Q zeigte sich eine Reduktion des infektiösen Virustiters in Abhängigkeit der 
Herkunft der Sequenz, die in das HCVcc Genom integriert wurde. Während diese Mutation im 
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AD78/JFH1 System zu einer sehr milden Beeinträchtigung der Infektiosität führte, wurde durch 
Einführung dieser Mutation in das H77/JFH11 System die Infektiosität dramatisch reduziert (> 6 
logs). Diese Daten lassen darauf schließen, dass der Einfluß von „escape“ Mutationen auf die 
virale Fitness zu einem großen Teil vom Sequenzkontext abhängig sein kann. 
 
Durch die Erstellung der HCV AD78 Sequenzdatenbank war es möglich eine strukturelle 
Besonderheit einiger HCV Stämme zu identifizieren, nämlich das Vorhandensein von 
zusätzlichen 1 - 5 Aminosäuren am N-Terminus des E2 Proteins. Die meisten der AD78 Isolate 
wiesen solche Insertionen auf. Mit Hilfe des HCVpp und HCVcc Systems wude der Einfluß 
dieser zusätzlichen Aminosäuren auf die virale Replikation und Infektion untersucht. Insertion 
dieser zusätzlichen Aminosäuren in das HCVpp System, basierend auf AD78 E1/E2 Sequenzen, 
und das AD78/JFH1 HCVcc System hatte keinen signifikanten Einfluß auf die Infektiosität 
dieser Partikel. Im Gegensatz dazu führte die Insertion der gleichen zusätzlichen Aminosäuren in 
das H77/JFH1 HCVcc System zu einem vollständigem Verlust der Infektiosität. Die genaue 
Analyse der zusätzlichen Aminosären zeigte auf, daß bevorzugt kleine, flexible Aminosären 
vorkommen, welche zum Erhalt der konformationellen Variabilität der HVR1 beitragen 
könnten. Dies wiederum könnte einige funktionelle Charakteristika des E2 Proteins, 
einschließlich seiner Antigeneigenschaften und Fähigkeit HCV Zellrezeptoren zu erkennen und 
zu binden, beeinflussen. 
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